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Abstract 
 
Introduction  
Chronic HIV-1 infection is characterized by immune activation and dysregulation of immune 
homeostasis, which impacts on multiple immune cell types. The B-cell compartment, which 
plays an important role in the producing neutralizing antibodies, is also dysregulated in HIV-
1 infection. In this study we investigated peripheral blood B-cell subset distribution, and 
changes in expression of cellular activation, inhibition, and apoptosis signaling markers in 
both untreated chronic HIV-1 infected individuals and healthy uninfected controls. The 
neuropeptide immune modulator, vasoactive intestinal peptide (VIP) is known to selectively 
down-regulate activation of CD4+ T-cells in various disease settings including HIV-1, 
however to our knowledge, no studies have investigated the effect of VIP inhibition on B-cell 
activation. 
Materials & Methods 
A total of 21 HIV+ve (CD4 count >250 cells/µl), and 19 HIV-ve individuals were recruited from 
the Emavundleni voluntary testing and counseling clinic in Crossroads, Western Province, 
South Africa. Whole blood was stained to distinguish B-cell subsets (activated memory (AM: 
CD21-CD27+), resting memory (RM: CD21+CD27+), mature naïve (MN: CD21+CD27-), or 
tissue-like memory (TLM: CD21loCD27lo). In addition expression of markers of B-cell 
activation (CD126, CD86, CD38, CD284, CD287), inhibition (CD72, CD85j, CD300a, 
CD305, CD307d), and apoptosis signaling (CD95), was assessed ex vivo by flow cytometry 
(BD FACSCanto II). For determination of functional responsiveness isolated B-cells 
(RosetteSep, Stemcell Technologies) were cultured for 18h (37°C, 5%CO2) without 
stimulation or stimulated with TLR ligands (LPS or R848). Stimulation experiments were also 
performed in the presence or absence of VIP. 
Results 
Chronic HIV-1 infection affected B-cell subset distribution. The percentage (%) of TLM was 
increased by 59.24%, and %RM was decreased by 22.73% (both p<0.01). Total expression 
of the VIP receptor VPAC2 was decreased by 47.35% (p=0.0296). Subsets had a mixed 
phenotype ex vivo; HIV infection upregulated CD38 (by 59.56%, p=0.0004), CD72 (by 
60.70%, p=0.0396), CD307d (by 68.63%, p=0.0015) on AM, while RM B-cells had increased 
expression of TLR4 (by 107.04%, p=0.0057) and TLR7 (by 208.14%, p=0.0199). TLM B-
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cells (i.e. exhausted phenotype) displayed upregulated TLR7 (by 550%, p=0.0128) and 
CD307d (by 72.40% p=0.045) expression. MN B-cells had increased CD72 expression (by 
70.98%, p=0.0026). R848 upregulated CD86 expression by 42.20% on AM (p<0.01), and by 
56.06% on RM B-cells (p<0.01), which was significantly downregulated with VIP inhibition 
(both p<0.05). Similarly, CD95 expression on RM, TLM, and MN B-cells increased by 
31.10% (p<0.001), 21.46% (p<0.01), and 39.92% (p<0.01) with R848 stimulation 
respectively, which was also significantly downregulated with VIP inhibition.  
Conclusion 
These data indicate that B-cells in untreated HIV infection display increased levels of 
activation, and also the potential for increased susceptibility to apoptosis as evidenced by 
increased FAS (CD95) expression. VIP significantly down-regulated markers of activation, 
inhibition, and apoptosis signaling. Dysregulation of B-cells is thus apparent in asymptomatic 
stable chronic HIV-1 infection, which may impact on both inefficient neutralizing antibody 
production and hypergammaglobulinemia. The ability of VIP to prevent stimulation-
associated marker upregulation may indicate that VIP is a potential therapeutic agent. Its 
immuno-modulatory properties were demonstrated to limit B-cell hyperactivation, and 
selectively down-regulate apoptosis and mark it out for further investigation. 
 
Opsomming 
 
Inleiding 
Immunaktivering en ongekoppelde immuun-homeostase is kenmerke van chroniese MIV-
infeksie. Ons het perifere bloed B-sel subgroep-verspreiding, en veranderinge in die 
uitdrukking van merkers van aktivering, inhibisie, en apoptose in 'n onbehandelde MIV-1 
besmettende groep ondersoek (in vergelyk met 'n gesonde onbesmettende kontrole). Die 
immuun-moduleerder, vasoaktiewe intestinale peptied (VIP) is bekend om aktivasie van 
geaktiveerde CD4+ T-selle te verminder, maar tot ons kennis, is daar geen studies wat die 
effek van VIP-inhibisie op B-sel aktivering ondersoek het, in die konteks van MIV-1 infeksie. 
Materiaal & Metodes 
MIV+we individue (CD4-telling >250 selle/µl) , en MIV-we kontroles is gewerf uit die vrywillige 
toetsing en berading Emavundleni kliniek, Crossroads, Westelike Provinsie, Suid-Afrika. B-
sel subgroepe is gedefinieer as geaktiveerde geheue (AM: CD21-CD27+), rusende geheue 
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(RM: CD21+CD27+), volwasse naïef (MN: CD21+CD27-), of weefsel-agtige geheue (TLM: 
CD21loCD27lo). Merkers van aktivering (CD126, CD86, CD38, CD284, CD287), inhibisie 
(CD72, CD85j, CD300a, CD305, CD307d), en apoptose signalering (CD95) is via 
vloeisitometrie (BD FACSCanto II) op B-selle ex vivo en ook op geïsoleerde B-selle 
(RosetteSep, Cell Technologies) ondersoek. Vir die bepaling van funksionele responsiwiteit, 
geïsoleerde B-selle (RosetteSep, StemCell Technologies) was vir 18h (37°C, 5%CO2) 
gekweek, sonder stimulasie of gestimuleer met TLR ligande (LPS of R848). Stimulasie 
eksperimente het ook in die teenwoordigheid of afwesigheid van VIP plaasgevind. 
Resultate 
Chroniese MIV-1 infeksie het B-sel subset verspreiding geraak. Die persentasie (%) van 
TLM is verhoog deur 59,24%, en% RM het met 22.73% afgeneem (beide p <0,01). Totale 
uitdrukking van die VIP reseptor VPAC2 het met 47,35% afgeneem (p = 0,0296). Subgroepe 
het 'n gemengde ex vivo fenotipe; MIV-infeksie het CD38 (deur 59,56%, p=0,0004), CD72 
(deur 60,70%, p=0,0396), CD307d (deur 68,63%, p=0,0015) op AM verhoog, terwyl RM B-
selle het verhoogde uitdrukking van TLR4 (deur 107,04%, p=0,0057) en TLR7 (deur 
208,14%, p=0,0199). TLM B-selle (die uitgeputtende fenotiep) het verhoogde TLR7 (deur 
550%, p=0,0128) en CD307d (deur 72,40% p=0.045) uitdrukking gewys. MN B-selle het 
verhoogde uitdrukking van CD72 (deur 70,98%, p = 0,0026). R848 het CD86 uitdrukking op 
AM deur 42,20%, en op RM deur 56,06% toegeneem (beide p <0,01). Dit het met VIP 
inhibisie beduidend afgeneem (beide p <0.05). CD95 uitdrukking was soortgelyk verhoog op 
RM, TLM, en MN B-selle met 31.10% (p <0.001), 21,46% (p <0,01), en 39,92% (p <0,01) 
met R848 stimulasie. Al drie het beduidend afgeneem met VIP inhibisie. 
Gevolgtrekking 
Hierdie data dui daarop dat B-selle in onbehandelde MIV-infeksie vertoon verhoogde 
aktiveringsvlakke, en ook die potensiaal vir verhoogde vatbaarheid vir apoptose soos bewys 
deur verhoogde uitdrukking van FAS (CD95). VIP het beduidend merkers van aktivering, 
inhibisie, en apoptose af-gereguleer. Wanfunksie van B-selle is dus in asimptomatiese 
stabiele chroniese MIV-1 infeksie duidelik, wat impak kan hê op beide oneffektiewe 
neutraliserende teenliggaampie produksie, en hiepergammaglobulinimie. Die vermoë van 
VIP stimulasie-verwante merker opregulasie te voorkom kan aandui dat VIP 'n potensiële 
terapeutiese agent is. VIP se immuno-moduleerende eiendomme is gedemonstreer om B-
sel hieperaktiveering te beperk, en selektief apoptose afreguleer, en merk dit vir verdere 
ondersoek. 
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 1 
Introduction 
Immune activation is one of the driving forces behind disease progression in untreated, 
chronic HIV-1 infection, where multiple immune cell types are affected including both T-cells 
and B-cells (Moir & Fauci, 2008). Numerous studies have shown that B-cells are 
hyperactivated and display poor functional responses in acute HIV-1 infection, and that 
these defects begin to emerge before the quantitative decline in CD4+ T-cells (Shen & 
Tomaras, 2011). While their primary function is that of antibody secretion, of particular 
interest in acute HIV-1 infection is the B-cell response to T-independent antigens, which 
engage mainly the toll-like receptor pathways and bypass isotype switching and affinity 
maturation. In doing so, the B-cell response to these innate stimuli is much faster, albeit not 
broadly-specific, resulting in secretion of IgM specific to the TLR-inducing antigens (Moir & 
Fauci, 2013). Furthermore in chronic, untreated HIV-1 infection, there is an abundance of 
both viral and bacterial antigen stimuli available to B-cells. Viral antigenemia is due to both 
ongoing HIV replication plus other chronic viral infections (e.g. CMV). Bacterial antigens are 
present due to destruction of gut-associated lymphoid tissue (GALT), leading to translocation 
of gut microbial antigens into the systemic circulation, providing an important source for 
ongoing activation of the immune system. Both bacterial components (e.g. 
lipopolysaccharide) and viral components (single-stranded RNA) antigens are considered to 
be T-independent antigens, capable of triggering toll-like receptors (TLR4 by LPS and 
TLR7/8 by ssRNA), both during acute and chronic HIV-1 infection (Lester, et al., 2008; 
Baenziger, et al., 2009). 
Immune exhaustion is another cardinal feature of untreated chronic HIV-1 infection, where 
effector cell responses are severely impaired as a result of persistent antigenic stimulation 
and immune activation (Klatt, et al., 2013). Decreases in cell function are correlated with 
increased presence of inhibitory receptors. On T-cells these include PD-1, Tim-3 and others; 
while on B-cells, receptors such as CD305, CD300a, CD85j, and CD72 confer inhibitory 
function (Kardava, et al., 2011). These receptors down-regulate activation signals, via 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails, which, 
when ligated, either block or significantly decrease the activity of cell signaling molecules. It 
is thought that expression of these receptors is up-regulated in response to persistent 
activation signals, and the cells are in fact trying to limit activation and the adverse 
pathological consequences thereof. However, in doing so, the cell compartments gradually 
lose their function (due to the fact that the activation signals, both viral and GIT-associated 
antigens, are never cleared), and HIV-1 disease progresses towards AIDS (Boasso & 
Shearer, 2008).  
Stellenbosch University  https://scholar.sun.ac.za
 2 
Current protocols for treatment of HIV-1 infection in South Africa are combination 
antiretroviral therapy (ART), with initiation of treatment being based on having a CD4 less 
than 350 cells/µl (Evans, 2013). ART is a potent inhibitor of viral replication; however, 
immune activation is not always adequately managed in those on treatment, and indeed the 
ongoing antigenic stimulation remains, mainly from bacterial antigens due to microbial 
translocation across the GIT. The GALT is a storage zone for multiple memory CD4+ T-cell 
populations specific for various antigens, and are the earliest cell population to be depleted 
in HIV infection due to apoptosis (following direct infection and/or activation-associated cell 
death). This process is thus a consequence of and a contributor to immune activation in 
primary infection (Klatt, Funderberg, & Brenchley, 2010). A useful adjunct to ART would be 
regimens which down-regulate activation signals without affecting the integrity of the immune 
response. The immuno-modulatory neuropeptide, vasoactive intestinal peptide (VIP) is 
known to selectively down-regulate activation signals on activated CD4+ T-cells (via the 
VPAC2 receptor), while not significantly affecting resting CD4+ T-cells (Ipp, et al., 2014). Of 
particular importance is the ability of VIP to downregulate Fas, thus protecting activated CD4 
T cells from activation-associated cell death. Little is known of the action of VIP, or its 
receptor VPAC2, on peripheral blood B-cells, and to our knowledge, this is the first study to 
investigate this. 
Our research question investigated whether B-cell responses of HIV-infected individuals to 
innate antigens (TLR ligands), such as bacterial LPS, and single-stranded viral RNA resulted 
in significantly altered expression of markers of activation, inhibition or exhaustion, and 
apoptosis signaling, as compared with HIV-uninfected controls. We also compared the 
expression of these B-cell markers with standard disease correlates such as CD4 count, HIV 
viral load, and CD38 expression on CD8+ T-cells. Once the responses to stimulation were 
established, we further investigated whether the novel immuno-modulatory neuropeptide, 
VIP could down-regulate TLR-induced expression of markers of activation, inhibition, and 
apoptosis signaling.  
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Chapter 1: Literature Review 
1.1 B-cell Physiology in Healthy Individuals 
1.1.1 Introduction 
B-cells play an important role in the mediation of humoral immunity via antibody secretion. 
The antibodies that are secreted in response to an infection bind to specific antigens on the 
pathogen’s surface, and in doing so aid in effective clearance of infection. Distinct antibody 
isotypes exist, each of which occupies a specific niche allowing specialised elimination of 
pathogens. 
1.1.2 Antigen independent B-cell development and maturation 
B-cells originate from common lymphoid progenitor cells, which in turn are derived from 
hematopoietic stem cells (Murphy, et al., 2008). Stromal cells within the bone marrow 
provide signals that stimulate early B-cell development, in the form of both membrane-bound 
and soluble chemokines and cytokines; and cellular interactions between cell-adhesion 
molecules and their respective ligands (Melchers, et al., 2000). The earliest cell of B-cell 
lineage is known as an early pro-B-cell (CD34+CD10+CD19+CD20-), where Ig gene 
rearrangement begins (Sanz, et al., 2010).  
The Ig heavy chain (IgH) gene recombination begins with the joining of the Diverse (D) and 
Joining (J) regions (see Fig 1.1), resulting in a unique D-J sequence where the cell becomes 
a late pro-B-cell (Melchers, et al., 2000). A second recombination then follows, in which the 
recombined Variable (V) region is joined to the D-J sequence, resulting in a unique intact µ 
heavy chain gene (Melchers, 2005). The resulting VDJ sequence is then joined to the 
Constant (C) region, and heavy chain gene recombination ceases to occur, and the cell 
becomes a Pre-B-cell. Approximately 45% of Pro-B-cells do not produce µ heavy chains, 
and are eliminated at this stage of their development (Melchers, et al., 2000). The newly-
produced heavy chains are tested for functionality by the formation of a pre-B-cell receptor 
(Pre-BCR), where the heavy chain combines with light chain-like proteins to signal to the 
pro-B-cell whether the VDJ recombination has been successful or not (Hardy & Hayakawa, 
2001). At this point the pre-B-cell is induced to proliferate, and recombination of the light 
chain genes occurs. An important concept in the gene recombination process is allelic 
exclusion, which is the process whereby only one of the two alleles of a diploid cell is 
expressed, due to the fact that successful recombination of the heavy chain of both alleles 
has the potential to produce two separate receptors with different antigen specificities, on the 
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same cell. This occurs in both heavy and light chain recombination (Pieper, Grimbacher, & 
Eibel, 2013). 
Light chain genes lack D segments, therefore only V and J rejoins to create a functional light 
chain protein (Fig. 1.1), and in the same manner as heavy chain recombination, the light 
chain genes are recombined on one chromosome, before proceeding to the other 
chromosome (Murphy, et al., 2008: pp.267). The light chain locus on human chromosomes 
can either be of the κ or λ type. Isotypic exclusion is the process whereby only one form of 
the light chain gene can be expressed, and in humans, the κ light chain locus has a 
tendency to recombine before the λ locus. If the eventual light chain gene recombination has 
been successful, the pre-B-cell is stimulated to proliferate, the resulting progeny being 
termed immature B-cells, which then express IgM (Melchers, 2005) 
Before the immature B-cell leaves the bone marrow (Fig. 1.2), its antigen receptor is tested 
for auto-reactivity in a process known as central tolerance (Kyewski & Klein, 2006). B-cells 
that cross-link strongly with a self-antigen in the bone marrow, will not mature, and undergo 
apoptosis or clonal deletion; or, will be induced into a state of immunological ignorance, or 
become permanently unresponsive (anergic). The immunologically ignorant cells however, 
can be activated in certain conditions, such as inflammation or with high levels of self-
antigen (Pieper, Grimbacher, & Eibel, 2013). Once the immature B-cells leave the bone 
marrow, they home towards the spleen, where they undergo further maturation and selection 
(Fig. 1.2). 
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Figure 1.1 Schematic overview of Heavy and Light Chain gene rearrangement.  
Early pro-B-cells first undergo joining of the D and J gene segments, which is followed by joining of 
the V region to the D-J sequence, which then joins the C region, resulting in an intact µ Heavy chain 
gene on a Pre-B-cell. Light chain genes lack the D region, soon the V and J sequences are joined to 
create a functional light chain. Adapted from Murphy, et al. (2008). 
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, 
 
Figure 1.2 Schematic overview of B-cell development from haematopoetic stem 
cell, to memory B-cell. 
 Adapted from Parham (2009). 
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1.1.3 Antigen dependent B-cell development and maturation 
1.1.3.1 Antigen Specific Activation: T-cell Independent Antigens 
T-cell independent antigens are non-proteinaceous (i.e. polysaccharides or nucleic acids), 
and can be further broken down into thymus-independent (TI) type 1, or TI type 2 antigens 
(Lanzavecchia & Sallusto, 2007; Fig. 1.3). As the name suggests, these antigens stimulate a 
B-cell response without the help of CD4+ T-cells, as APCs do not normally process and 
present these types of antigen via the major histocompatibility complex (MHC) to naïve CD4 
T cells, which is required for promoting B-cell help (Rawlings, et al., 2012). TI type 1 
antigens comprise TLR-ligands such as LPS or viral RNA and result in the formation of 
memory B-cells, in contrast to TI type 2 antigens, which are multivalent, consisting mainly of 
repeating epitopes such as bacterial capsular polysaccharides or viral capsid proteins, which 
do not result in formation of memory B-cells (Vinuesa & Chang 2013). TI type 2 antigens 
cross-link the BCR upon ligation, leading to activation. The alternate complement pathway 
activates B-cells in a similar fashion, where antigen-bound C3d leads to BCR signaling via 
recruitment of CD21, and C4-binding protein can provide a CD4+ T-cell-like signal via CD40 
engagement (Lanzavecchia & Sallusto, 2007). Antigen-presenting cells (APCs) such as 
macrophages and dendritic cells (DCs) produce pro-inflammatory soluble mediators such as 
the cytokines interleukin (IL) -2, IL-4, interferon (IFN) –α, among others, that stimulate the 
BAFF (B-cell activating factor) family of receptors that provide additional signals for B-cell 
activation (Rawlings, et al., 2012). During the acute phase of HIV-1 infection, pattern 
recognition receptors (PRRs) such as TLRs are among the first means of identifying the 
invading virus, chief among which is TLR7, recognizing ssRNA in endosomal vesicles (He, 
et al., 2013). Indeed, TLR signaling has been described as pivotal in both an initiator of and 
contributor to the ongoing immune activation in HIV infection (Siewe, et al., 2013). 
 
1.1.3.2 Antigen-Specific Activation: T-cell-Dependent Antigen Presentation 
APCs reside in areas of environmental contact within the body, such as the skin, and 
mucosae. APCs such as DCs and macrophages can be considered the ‘sentinels’ of the 
immune system, in that they constantly survey the extracellular milieu of these sites for both 
foreign and self-antigens. DCs are of particular interest due to their migratory capacity, and 
the fact that they are prime stimulators of naïve T-cells in lymphoid tissues. Once a DC has 
encountered Ag, in the presence of pro-inflammatory cytokines such as IL-1, IL-6 and TNF–
α, it up-regulates co-stimulatory molecules (CD40, CD80, CD86) and cytokines (IL-1, IL-12, 
TNF-α) and migrates to T-cell areas of peripheral lymphoid tissue (Steinbrink, et al. 2009). 
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DCs then activate naïve CD4+ T-cells which then become reactive towards the specific Ag if 
it is foreign or pathogenic, whereas if the Ag is that of the body (self-Ag), the CD4+ T-cell 
becomes nonreactive or tolerant towards the self-Ag. 
The CD4+ T-cells then proceed to alter surface molecule expression by up-regulating CD40 
ligand (CD40L) and altering chemokine receptor expression (increased CXCR5 and 
decreased CCR7 expression). These CD4+ T-cells (also known as helper T-cells) migrate 
towards the lymphoid follicle down a CXCL13 chemokine gradient (secreted by follicular 
DCs). At the same time, naïve B-cells are activated when they encounter antigen via the 
BCR and also TLRs in peripheral environmental contact sites. On encountering antigen, they 
down-regulate CXCR5 and up-regulate CCR7 expression, and subsequently migrate out of 
the follicles and meet the activated CD4+T-cells. CD40, which is constitutively expressed by 
B-cells, interacts with CD40L on the activated helper T-cells and induces the transcription 
factors NF-κB and AP-1. The activation of these transcription factors allows genes crucial to 
the germinal centre reaction to be transcribed (Tarlinton, 2006). 
1.1.3.3 The Germinal Centre Reaction 
The germinal centre is an area of the lymphoid follicle that Ag-activated B-cells migrate to in 
order for rapid B-cell proliferation to occur (Klein, et al., 2003; Fig. 1.3). The germinal centre 
can be divided into two areas based on appearance in microscopic section, namely the dark 
and light zones consisting of rapidly proliferating B-cells (known as centroblasts), and B-cells 
undergoing selection, respectively (Tarlinton, 2006). The B-cells in the dark zone undergo 
somatic hypermutation, which is the process whereby point mutations occur within the V, D 
and J immunoglobulin (Ig) genes to create more diversity in Ag-recognizing capacity. This 
process is not to be confused with V(D)J recombination, which occurs in the bone marrow as 
part of B-cell development. Once somatic hypermutation has occurred, the B-cells then 
proceed towards the light zone of the germinal centre, where their Ag-recognising ability is 
tested by follicular dendritic cells (Tarlinton, 2006). B-cells with high-affinity Ig receptors are 
selected to survive and mature further, while those with low-affinity or non-binding Ig 
receptors are selected for death. This process ensures that only B-cells with highly-specific 
Ig receptors towards a particular Ag are involved in the further immune response (Phan, et 
al, 2006). 
1.1.3.4 Class-Switching 
Class switching refers to the process of Ig receptor isotype alterations in response to specific 
types of Ag, resulting in either IgM, IgG, IgE, or IgA production (McMichael, et al., 2010). The 
mechanism whereby class switching occurs is known as switch recombination, and during 
this process the rearranged VDJ genes recombine with a downstream C region gene. CD40 
and cytokine stimulation induces transcription via the C region gene (known as germline 
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transcription) resulting in different Ig isotype production in response to different types of Ag, 
through the CD4+ T-cell interaction. Many non-protein innate Ag’s such as LPS are not 
recognized by T-cells, and subsequently CD4+ T-cell help does not occur, with the B-cells 
retaining their IgM isotype. Viral and bacterial protein Ag activates TH1 T helper cells, which 
produce IFN-γ, a key inducer of IgG isotype switching (Siegrist & Aspinall, 2009) 
 
Fig 1.3: Schematic overview of the B-cell antigen response to either polysaccharide Ag (T-
independent), or protein Ag (T-dependent). A) Polysaccharide antigens reach the marginal zone of 
lymphoid tissues and bind to marginal zone B-cells, thereby driving their differentiation into short-lived plasma 
cells in the absence of T-cell help. B) Protein antigens arrive at the B-cell zone in the lymph nodes either by 
diffusion (triggering the T-independent response), or by DC trafficking and presentation in the T-cell zone 
(triggering T-dependent responses). This results in the generation of both short-, and long-live plasma cells; as 
well as long-lived memory B-cells. Adapted from Siegrist & Aspinall (2009).  
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1.1.3.5 Affinity Maturation 
Affinity maturation is a process, which leads to increased antibody affinity (i.e. binding 
strength) towards the specified Ag. Affinity maturation also only occurs when protein Ag is 
encountered (that is, CD4+ T-cell-dependent antigen), due to the CD40-CD40L interaction, 
which is a prerequisite for this process (therefore affinity maturation does not occur in the 
presence of non-protein Ag with innate stimulation) (McMichael, et al., 2010). As mentioned 
above, B-cells with non- or poorly-reactive Ig towards the specific Ag (due to somatic 
hypermutation) are selected to undergo apoptosis by the follicular DCs. Therefore the B-cells 
that survive are those that can bind Ag, and due to the nature of somatic hypermutation, B-
cells with increasingly strongly-binding Ig are produced. Therefore, the crux of affinity 
maturation is that the constantly rearranging Ig-genes produce B-cells with Ig that have 
increasing binding strength towards the defined Ag (Pulendran & Ahmed, 2011).  
1.1.3.6 B-cell Memory 
The cells that have been selected for survival by the follicular DCs then exit the germinal 
centre and proceed to differentiate into either memory B-cells, or plasma cells highly-specific 
for the Ag in question (Tangye & Tarlinton, 2009). Memory cells are long-lived cells, which 
recognize and rapidly respond to previously-encountered Ag. Memory cells in peripheral 
circulation and in lymph nodes become Ag-specific plasma cells in response to recall Ag (i.e. 
Ag that has already been encountered); this secondary or repeat Ag response is much more 
rapid than the primary or initial Ag response (Tarlinton, 2006). 
Plasma cells are terminally differentiated B-cells with a distinctive morphology that produce 
large amounts of Ag-specific antibodies. They are found mainly in the extra-follicular sites of 
the lymphoid organs (i.e. the lymph node medulla and splenic red pulp) and consist of two 
distinct types, namely the long- and short-lived plasma cell (Siegrist & Aspinall, 2009). As 
mentioned above, CD40 and cytokine stimulation (such as IL-2, IL-4 and IL-6) result in B-cell 
differentiation into plasma cells, which is mediated by the transcription factor BLIMP-1 (also 
known as PR domain zinc finger protein 1). Short-lived plasma cells are generated in 
response to thymus-independent Ag, which do not induce a T-cell response, while long-lived 
plasma cells home to the bone marrow and are sustained by BCMA (B-cell Maturation 
Antigen, also known as TNFR superfamily 17) receptor stimulation. These long-lived plasma 
cells continue to produce antibodies for years, even in the absence of antigenic stimulation, 
with the bone marrow becoming the primary site of antibody production (Tangye & Tarlinton, 
2009). 
1.1.4 B-cell Subsets 
B-cells inhabit many niches within the human immune system, and have surface markers 
characteristic to each niche. As mentioned above, B-cells develop in the bone marrow from 
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haematopoietic stem cells (HSC), once they reach the immature B-cell stage of 
development; they migrate out of the bone marrow into the blood stream, towards secondary 
lymphoid organs, where further maturation and development takes place. 
B-cells can be identified primarily by their expression of both CD19 and CD20, also known 
as pan-B markers. CD19 is expressed on the surface of pro-B-cells in the bone marrow, and 
lost on long-lived plasma cells, while expression is maintained on long-lived memory B-cells 
(Hardy & Hayakawa, 2001). CD20 expression is gained on the B-cell surface at the pre-B-
cell stage of development and is lost in plasmablasts (Eisenberg & Looney, 2005). CD19 
expression is essential for normal antibody responses, and defects in CD19 expression 
cause delays in maturation, proliferation and antibody production (Wang & Carter, 2005). 
CD20 is highly expressed on the cell surface, and is a therapeutic target in B-cell 
lymphomas, where the anti-CD20 drug Rituximab has been shown to effectively deplete 
peripheral blood B-cells in vivo (Eisenberg & Looney, 2005). 
1.1.4.1 Peripheral Blood Subsets 
The five major peripheral B-cell subsets to be discussed and which are the focus of this 
study are as follows: Transitional (immature) B-cells, mature naïve B-cells, activated memory 
B-cells, resting memory B-cells, and plasmablasts. All of the above-listed subsets express 
CD19, while plasmablasts and transitional B-cells express variable levels of CD20. 
Transitional/Immature B-cells are CD10+ B-cells that were first described in patients with 
Systemic Lupus Erythematosus (SLE) who underwent B-cell depletion therapy with 
Rituximab, and they have also been reported in chronic HIV infection, as well as other states 
of immunodeficiency such as Common Variable Immunodeficiency (CVID) and Idiopathic 
CD4+ Lymphocytopenia (ICL) (Moir, et al., 2010). Healthy individuals have low circulating 
number of these cells, which increases in frequency in diseases such as chronic HIV 
infection. This is due to increased serum levels of IL-7, which is produced as a homeostatic 
compensation mechanism to the CD4 lymphopenia of HIV infection (Ho, et al., 2006). 
Human transitional B-cells can be subdivided into separate populations based on the 
expression of CD24 (an undefined sialoglycoprotein) and CD38 (cyclic ADP ribose 
hydrolase). T1 B-cells (CD10+CD24hiCD38hi) are found primarily in peripheral blood, and T2 
B-cells (CD10+CD24hiCD38lo) are mostly restricted to the spleen (Sims, et al., 2005). The T1 
population bears a striking phenotypic resemblance to that of hematogones, which are non-
malignant B-cell precursor cells (Agarwal, et al., 2010). There appears to be conflicting 
information with regard to whether transitional B-cells are indeed hematogones, Sportès, et 
al (2010) for example refers to transitional B-cells and hematogones as two distinct entities.  
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Mature naïve B-cells constitute the largest portion of peripheral blood B-cells. They are 
antigen-naïve cells, characterized by high surface expression of complement receptor 2 
(CR2) also known as CD21 and negativity for CD27 (a member of the TNFR superfamily). 
These cells are the mature form of transitional B-cells, and are short lived (Ettinger, et al., 
2005). In fact, approximately 50% of these cells die every 3 days in the steady state, when 
not exposed to Ag (Murphy, et al., 2008: pp.304).  
Memory B-cells are classified according to their expression of CD27 and CD21, and can be 
either activated, or resting. CD27 positivity distinguishes both activated- and resting memory 
cells from naïve cells, while CD21 expression represents the ability to internalise immune 
complexes, therefore cells with CD21- or CD21lo expression have a decreased ability to 
recognize complement-bound Ag (Das, et al., 2011). Erdei, et al. (2009) found that survival 
of memory B-cells was impaired when CD21 was not expressed. CD21loCD27hi expression 
characterises memory B-cells with an activated phenotype, that is, memory B-cells that are 
proliferating and in the process of differentiating into plasma cells. 
Plasmablasts are the immature, actively dividing form of plasma cells, which exist in 
circulation for a few days before they cease to divide and either undergo apoptosis, or 
further differentiate into plasma cells and migrate towards lymph nodes, or the bone marrow 
(Fairfax, et al., 2008). Plasmablasts can be defined by the high expression of CD38, and 
absence of CD138 (Syndecan 1), and have the following immunophenotype: CD20-
CD19+CD27hiCD38hiCD138- (Llinàs, et al., 2011). Plasmablasts lose CD19 and CD20, and 
gain CD138 expression as they mature into plasma cells and subsequently migrate to the 
bone marrow (Pinto, et al., 2013). 
 
1.2 Human Immunodeficiency virus 
1.2.1 HIV epidemiology in South Africa 
A report by the Joint United Nations Program on HIV/AIDS estimated that as of 2013, there 
are more than 35 million people living with HIV world-wide (UNAIDS, 2014). At least 24.7 
million of these people live in Sub-Saharan Africa, representing approximately 70.6% of the 
global HIV burden. 6.3 million HIV-infected individuals live in South Africa; with the largest 
population of HIV-infected individuals in the world. This number corresponds to 
approximately 10% of the South African population (UNAIDS, 2014).  
Since the rollout of antiretroviral therapy (ART) in 2004, there has been a dramatic decrease 
in the number of new infections in South Africa (Evans, 2013). Approximately 86% of people 
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with known HIV status in Sub-Saharan are receiving treatment, 76% of which have achieved 
viral suppression. South Africa has an HIV treatment coverage of more than 72% (UNAIDS, 
2014). It is estimated that, since 1995, ART has prevented more than 4.8 million deaths in 
sub-Saharan Africa (UNAIDS, 2014). 
1.2.2 Immunopathogenesis of HIV-1 infection 
A hallmark feature of HIV-1 infection is the loss of CD4+ T-cells. Both direct infection and 
“bystander” death are implicated in this CD4+ T-cell loss. CD4+ T-cells are the main targets 
for HIV-1 infection via the interactions of gp120 membrane glycoprotein on the HIV-1 virion 
with the CD4 receptor. In addition, entry requires interaction with either the CCR5 or CXCR4 
chemokine co-receptors on the CD4+ T-cell (Haase, 2010). Once gp120 has bound to CD4 
and its co-receptors (mediated by the HIV-1 membrane glycoprotein gp41) fusion of the two 
entities occurs, which allows entry of viral core and subsequent release of viral RNA and 
reverse transcriptase (RT) into the CD4+ T-cell cytoplasm. Thereafter, RT-mediated reverse 
transcription of viral RNA into cDNA occurs, which is then integrated into the host’s genome 
via the virally-encoded HIV-integrase enzyme. The integrated provirus can then be 
replicated (in activated CD4+ T-cells) and encode for viral proteins which allows for 
assembly of new virions which bud off at the CD4 T-cell membrane (Klatt, et al., 2013).                                  
The most common route of HIV transmission in Sub-Saharan Africa is via heterosexual 
intercourse, and therefore it is important to understand the dynamics of HIV transmission at 
mucosal sites (UNAIDS, 2012). Experiments using a non-human primate model of mucosal 
HIV transmission have demonstrated that HIV can cross the mucosal barrier within hours, 
subsequently producing a so-called ‘founder population’ of infected resting CD4 T-cells 
(Haase, 2010). The next 10 or so days following primary infection is known as the ‘eclipse’ 
phase, where there is no detectable viral RNA in the plasma. The founder population then 
expands sufficiently to disseminate throughout the secondary lymphoid organs and 
establishes a self-propagating infection in what is known as acute HIV syndrome (Fig. 1.4, 
Fauci, 1996). This stage of HIV-1 infection is characterized by several pathophysiological 
events, the most profound being a rapid increase in HIV-viraemia. While HIV directly infects 
only 20% of the total CD4 population in the GALT, an additional 60% undergo apoptosis in 
response to activation signals (including pro-apoptotic cytokines and death receptor ligands 
such as TNF-α, TRAIL, and FasL) from the infected cells. Altogether, about 80% of GALT 
CD4+T-cells are depleted within the first 3 weeks of HIV-1 infection (McMichael, et al., 2010). 
B-cell dysfunction is evident at this early stage despite the lack of direct infection of these 
cells by the virus. This dysfunction is related to the loss of cell populations crucial to the 
formation of germinal centers. Approximately 50% of germinal centers in the GALT are lost 
in the acute phase of HIV-1 infection (McMichael, et al., 2010). 
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Peak plasma viraemia occurs towards the end of the acute phase of HIV-1 infection, and 
begins to decrease to a more stable level known as the viral set point, which is maintained 
by a homeostasis between viral turnover and the adaptive immune system (Ostrowski, 
2010). The chronic phase of HIV-1 infection (referred to as ‘clinical latency’ in Fig. 1.4) that 
follows can last between weeks and years before the onset of the clinical symptoms of AIDS. 
At this stage of infection, inflammation caused by the initial viral infection remains 
unresolved, thereby resulting in chronic stimulation of the immune system resulting in 
immune activation (Fig. 1.4 below), which further drives systemic inflammation (Desai & 
Landay, 2010).
Fig. 1.4 Typical course of HIV infection. Adapted from Fauci (1996) 
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1.3 HIV-related inflammation & Immune Activation, and B-cell 
Dysfunction 
1.3.1 General Features of Inflammation and Immune Activation in HIV 
Immune activation is defined by Appay & Sauce (2009) as “A rather broad expression that 
covers a large range of events or observations involved in active molecular or cellular 
processes…and their consequences”. Immune activation in HIV-1 infection has been linked 
to direct infection by HIV-1, increased pro-inflammatory cytokine production by innate cells 
(which further drives both bystander, and direct cellular activation), increased systemic LPS 
and other microbial products due to microbial translocation, other co-infections, and loss of 
regulatory T-cells (McMichael, et al., 2010). HIV-associated immune activation has been 
linked to HIV-viremia, lymphopenia, and microbial translocation in the GIT (Ruffin, et al., 
2012). Ongoing immune activation is one of the characteristic features of chronic HIV 
infection, which occurs while viraemia is still relatively well-controlled. Predictive markers of 
disease progression vary, although both CD4 count and plasma HIV-1 viral load are used to 
monitor immune status, and viral burden (Siliciano & Siliciano, 2010). The well-described 
marker of immune activation: CD38 expression on CD8+T-cells is an increasingly-relevant 
means of assessing HIV-1 disease progression (Appay & Sauce, 2009) 
Immune activation results in an increased expression and up-regulation of biomarkers 
associated with activation (both soluble and membrane-bound), increased cellular 
proliferation and apoptosis, and an increase in the secretion of inflammatory biomarkers 
such as growth factors, chemokines, and cytokines (Kiazyk & Fowke, 2008). Markers of B-
cell activation, demonstrated to be elevated as a consequence of immune activation during 
chronic HIV infection include CD70, CD71, CD80, CD86, and CD23 (Moir, et al., 2008). 
Recent studies report an increase in IL-21R expression (Ruffin, et al., 2012), as well as 
increased expression of PD-1 and decreased BTLA (B and T-Lymphocyte Attenuator) 
expression on B-cells, the implications of which are similar to that of increased CD38 and 
PD-1 on CD8+T-cells in chronic HIV infection (Boliar, et al., 2012). In addition, the loss of 
CD28 (the receptor for CD80 and CD86) and increased CD57 (human natural killer-1, an 
adhesion molecule) expression have been described (Desai & Landay, 2010). Activated 
memory B-cells in chronic (untreated) HIV infection are also more prone to apoptosis, with 
increased expression of Fas (CD95) (Moir, et al., 2010). 
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1.3.2 Direct Interactions Between HIV and the B-cell Compartment 
Immune activation has been associated with persistent antigenic exposure resulting in the 
immune system constantly being in an activated state against the perpetual presence of 
viral, (translocated) GIT products, and opportunistic/chronic non-HIV infection antigens 
(Badley, et al., 2000). Immune activation is a normal response to acute infection; is usually 
short-lived and decreases as the foreign Ag is cleared. In untreated HIV, however, the Ag is 
never cleared, and its constant presence results in a state of chronic immune activation 
(Malaspina, et al. 2003). In this manner, the direct interactions between HIV and the immune 
system cause several abnormalities in the B-cell compartment. 
HIV virions opsonised by complement and HIV envelope proteins such as gp120 and nef are 
involved in the direct interaction between HIV and B-cells, via complement receptors and the 
BCR respectively (Moir & Fauci, 2008). Gp120 binds to C-type lectins (such as DC-SIGN, 
also known as CD209) on the B-cell membrane, and in so doing, induces immunoglobulin 
class switching, and increased levels of its related enzyme, activation-induced 
cytidinedeaminase (AID) (Moir & Fauci, 2009). However, Moir and Fauci in 2008 reported 
seemingly conflicting data, where, in an in vitro model, nef had been found to accumulate 
within endosomes in B-cells and interfere with CD40L-mediated signaling, thereby inhibiting 
immunoglobulin class switching and activation.  
TLR signaling by TLR ligands is a separate pathway to that of BCR-mediated signaling, and 
also serves as a means of direct innate stimulation of B-cells by HIV. TLR 7 and 9 are both 
viral sensors that recognize ss-RNA and CpGDNA sequences, respectively (Haas, et al., 
2011). Constitutive TLR signaling in B-cells in humans is restricted to the memory 
compartment, and upregulation of TLRs on naïve B-cells requires BCR-mediated signaling, 
usually via type 1 IFNs (Lanzavecchia & Sallusto, 2007). An indirect means of in vivo B-cell 
stimulation by TLRs (to be discussed further on) is via TLR4 signaling, which recognizes 
bacterial LPS from the GIT (Mauri & Bosma, 2012). 
1.3.3 Indirect Interaction between HIV and the B-cell Compartment 
In addition to the direct effect of HIV on the immune system, there is an indirect effect of the 
infection on immune activation. Pro-inflammatory cytokines and growth factors such as IFN-
α, TNF-α, IL-6, IL-10, CD40L (Appay & Sauce, 2009) and BAFF (Shen & Tomaras, 2011) 
are thought to contribute towards the aberrant activation of B-cells in HIV-viremic individuals, 
due to their increased serum levels during HIV-infection (Moir, et al, 2011). These soluble 
mediators are produced by cells of the innate immune system in response to HIV infection. 
Plasmacytoid dendritic cells (pDC) play an important role in this so-called ‘first line of 
defense’ against viruses, via production of type 1 interferons (such as IFN-α, which inhibits 
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viral replication) and induction of IDO (indoleamine 2,3-dyoxigenase), which plays a role in 
immune tolerance and the suppression of T-cells under normal physiological conditions 
(Boasso & Shearer, 2008). Other important secretors of inflammatory mediators are 
macrophages, which are known to secrete proinflammatory cytokines such as TNF-α, IL-1β, 
and IL12 in response to CD4+ T-cell apoptosis (Ostrowski, 2010) 
1.3.4 Chronic Innate Immune System Activation 
The innate immune system is an important first line of immunological defense as it is the first 
cellular compartment to respond to pathogenic stimulation (Haase, 2010). Antigen-
presenting cells have high concentrations of pattern-recognition receptors on their cell 
surface, which recognize several highly-conserved classes of molecular structures 
associated with groups of micro-organisms, known as pathogen-associated molecular 
patterns (PAMPs) (Kanzler, et al, 2007). When APCs encounter PAMPs such as bacterial 
LPS (or host-derived damage-associated molecular patterns, known as DAMPs), they 
induce an inflammatory response that results in recruitment of cells of both the innate and 
adaptive immune systems to sites of infection. The APCs (primarily DCs), having engulfed 
the antigen, proceed to migrate to secondary lymphoid organs and present the processed 
antigen to cells of the adaptive immune system, and initiate an adaptive immune response 
(Gonzalez, et al., 2011). 
The chronic stage of HIV infection can be characterized by sustained activation of the innate 
immune system due to the presence of viral antigen (both HIV and other chronic reactivated 
viruses e.g. CMV) and ongoing exposure of innate immune cells to gut microbes, or their 
products, due to the ‘leaky gut’ phenomenon (Appay & Sauce, 2009). The ’leaky gut’ 
phenomenon refers to the damage inflicted on the GIT following massive localized HIV 
infection and depletion of CD4+ T-cells from the GALT (during acute HIV-1 infection). As a 
result of this massive loss of CD4+ T-cells, the integrity of the mucosal epithelium is 
disrupted and this surface in effect becomes permeabilized, leading to what’s known as HIV 
enteropathy (Brenchly & Douek, 2008 [1]). The subsequent epithelial permeability creates 
the scenario of microbial translocation, whereby bacteria, other microorganisms and their 
products enter the circulation and cause further immune activation at the GALT sites and 
systemically. The presence of these microorganisms in the setting of increasing HIV-related 
immunosuppression leads to an additional mechanism for opportunistic infections to occur, 
and enhance the progression to AIDS (Brenchly & Douek, 2008 [2]). 
Chronic immune activation ultimately manifests as the inability of the immune system to 
mount an appropriate response to antigenic stimulation. pDCs initiate the first anti-viral 
response within the first few hours of infection in the form of IFN-α, which limits viral 
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replication in the short-term while an adaptive, antigen-specific immune response is 
developed (Boasso & Shearer, 2008). Markers of pDC activation (Type 1 IFN and IDO) 
normally decrease after the acute phase of infection when the adaptive immune response is 
initiated, but in the case of HIV, the levels of these markers remain elevated, despite the 
initiation of the adaptive immune response. The inability of the adaptive immune response to 
clear the infection, as well as the immune down-regulatory effect of IDO (which further 
inhibits the adaptive immune response) contributes towards the persistence of, and shift 
towards the chronic stage of HIV infection (Boasso & Shearer, 2008). 
An additional contributing factor to chronic immune activation occurs within the germinal 
centre, via follicular dendritic cells (fDC) antigen presentation. These APCs present antigen 
to naïve B- and T-lymphocytes in the lymphoid germinal centers during lymphocyte 
development. However, continuous viral replication results in persistent exposure of fDCs to 
virions. These virions are then continuously presented to the naïve lymphoid cells, which 
persistently stimulates them, as well as exposing CD4+ T-cells to infection (Fauci, 1996). 
Similarly, myeloid DCs (also known as conventional DCs) in the body’s periphery also play a 
role in persistent stimulation by capturing and processing viral antigens in the periphery, and 
then migrating towards the lymphoid follicles to present Ag to B- and T-cells (Steinman & 
Banchereau, 2007). 
This poses a vicious cycle of the immune activation in chronic HIV infection, whereby APCs 
unwittingly contribute to immune activation, further viral replication, as well as continuous 
immune suppression. 
1.3.5 Chronic Adaptive Immune System Activation  
1.3.5.1 T-cell Response to HIV 
Although multiple immune cell types are affected by HIV-1 infection, as mentioned 
previously, the CD4+ T-cell population is perhaps the most affected immune compartment. 
The CD4+ molecule present on the ‘helper’ T-cell population is the primary target of the HIV, 
and is a membrane-bound receptor that forms part of the T-cell receptor complex. It plays a 
role in T-cell activation, which occurs when it interacts with MHC class II on APCs (Haase, 
2010).  
There exists a detrimental interplay between T-cell activation and viral replication, in that HIV 
infects and replicates primarily in activated T-cells, subsequently resulting in an increased 
plasma viral load and propensity towards T-cell apoptosis, but also an increased level of T-
cell activation. Therefore, CD4+ T-cells inadvertently contribute towards their depletion by 
responding to (HIV) antigen (Brenchley & Douek, 2007). Direct T-cell infection by HIV is not 
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a primary driver of T-cell apoptosis, due to the number of directly-infected cells being 
significantly fewer than the total number of cells undergoing apoptosis (Hazenberg, et al. 
2003). The incessant T-cell decline, in spite of a steady viral load, can therefore be attributed 
to more indirect means, such as that induced by immune activation and inflammation which 
result in a process known as ‘bystander cell death’ of uninfected CD4+ T cells (Kiazyk & 
Fowke, 2008). 
1.3.5.2 B-cell Hyperactivity 
HIV infection, and its subsequent immune activation cause a number of disturbances in the 
B-cell compartment, namely hypergammaglobulinemia, polyclonal B-cell activation, and 
impaired reactivity to immunization and in vitro activation signals (De Milito, 2004). Other 
notable abnormalities include increased cell turnover, activation marker expression, and 
autoantibody expression, as well as an increase in the frequency of HIV-related B-cell 
malignancies (Moir & Fauci, 2009). 
Hypergammaglobulinemia refers to the raised presence of gammaglobulins in circulation, 
which are predominantly IgM, however other antibody classes are also involved. These 
antibodies comprise both of HIV- and non-HIV antibodies, the latter of which consists of low-
affinity- and auto-antibodies (that is, self-reactive antibodies), whose presence is indicative 
of dysregulated CD4 T-cell help (De Milito, 2004). In the context of HIV infection, the pro-
inflammatory state that exists is conducive to B-cell activation and class switching from the 
IgM to IgG isotypes (De Milito, et al., 2004).  
In the acute phase of HIV infection, complement proteins bound to HIV virions bind to the 
CD21 (complement) receptor, which induces polyclonal activation and terminal differentiation 
of B-cells (Shen & Tomaras, 2011). This results in, among other things, the generation of 
antibody-secreting plasma cells, whose presence, in the form of antibody-virion immune 
complexes is first detectable at around 19 days post-infection (Levesque, et al. 2009). 
Furthermore the same authors reported that functionally active neutralizing antibodies only 
appeared in serum around 12 weeks after infection, compared to priming immunizations with 
non-pathogenic, non-HIV-1 viruses, which elicited a peak neutralizing antibody titer at 
around 14 days post-infection. HIV thus appears to evade the initial adaptive immune 
response. The constant presence of HIV-antigens in serum during chronic HIV infection can 
be said to be a major contributor towards HIV-associated immune activation and de-
regulation, including B-cell dysregulation (Appay & Sauce, 2009).  
Memory B-cell numbers are significantly decreased in the peripheral blood of individuals with 
chronic HIV infection, and are prone to die by apoptosis (Titanjiet al. 2006). However, Moir 
and Fauci (2008) found this to be a somewhat contradictory finding due to the fact that 
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memory B-cells are characterized by the expression of CD27, which is also a marker of 
terminal differentiation and activation. As these two features are significantly over-
represented in chronic HIV infection, CD27 alone does not reflect true memory B-cells. The 
authors suggest that CD21, CD20 and CD19 can be used to distinguish between memory B-
cells and aberrantly activated B-cells. As a result of a defective memory B-cell compartment, 
response to both new and recall antigens is severely defective in individuals with chronic HIV 
infection (De Milito, 2004). Serum antibodies against both viral and bacterial antigens such 
as those of measles and S. pneumonia, respectively, have been found to be decreased in 
chronically HIV-infected patients, and did not increase significantly (compared to controls) 
with antiretroviral therapy (ART) (Titanji, et al, 2006). The same authors proposed that the 
impairment of serologic memory could be due to the immense viral replication that takes 
place during primary HIV infection, which may be responsible for the depletion of antigen-
specific memory B-cells through altered TNFR expression and apoptosis. Such defective 
immune memory may play an important role in the development of opportunistic infections 
during chronic HIV infection. 
1.3.5.3 B-cell Malignancies Associated with Hyperactivity and Exhaustion 
Several malignancies, such as Kaposi sarcoma, non-Hodgkin lymphoma (NHL), and cervical 
cancer, have been associated with HIV infection, and as such have been classified as AIDS-
defining malignancies (ADMs) by the Centers for Disease Control and Prevention (Dauby, et 
al., 2011). However, with the advent of HAART, there has been both a decrease in ADM’s, 
as well as a significant increase in non-AIDS defining malignancies (NADM) such as 
Hodgkin’s lymphoma, anal, lung and liver cancers (Dauby, et al., 2011). HIV-related NHL 
represents the largest fraction of HIV-associated malignancies, and it is most often 
comprised of a single malignant clone, which has frequent involvement of extranodal sites, 
and is indicative of poor prognosis (Capello, et al., 2009). A proposed means of 
lymphomagenesis is via B-cell activation, due to the fact that many B-cell stimulatory factors 
are elevated in serum, such as IL-6, IL-10, BLyS, and CXCL13 (Thapa, et al., 2012). The 
same authors found that miR-21 levels (a B-cell oncogene and marker of poor prognosis) 
levels were higher in activated B-cells from lymphoid organs (i.e. sites of activation) 
compared to peripheral blood subsets (Thapa et al., 2012). 
‘Exhaustion’ of immune cells is a concept that arose in T-cell immunology, and refers to a 
stage of differentiation where there is increased expression of multiple inhibitory receptors, a 
reduced expression of activation markers, and a decrease in functional capacity of a specific 
T-cell (Küppers, 2008). Exhausted B-cells are characterized by elevated expression of the 
inhibitory receptors programmed cell death receptor 1 (PD1) and cytotoxic T-lymphocyte 
antigen 4 (CTLA4). In addition elevated CD20 expression, low expression of CD21 and 
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CD27, and expression of Fc-receptor-like 4 (FCRL4) has been observed (Moir & Fauci, 
2008). These B-cells, also known as Tissue-like memory B-cells, are similar to exhausted T-
cells due to their loss of proliferative, effector, and homing properties (Moir & Fauci, 2008). 
1.3.6 The Impact of Antiretroviral Therapy 
1.3.6.1 Antiretroviral Therapy in South Africa 
Since its inception in 1996 (and rollout in 2004 in South Africa), HAART has resulted in a 
considerable and prolonged decrease in the progression of HIV to full-blown AIDS disease 
(Lichtenstein, 2009; Evans, 2013). HAART consists of a regimen of different classes of 
ARVs, usually consisting of reverse transcriptase-, integrase-, and protease inhibitors, 
whose primary mechanism of action is to inhibit viral replication, thereby decreasing plasma 
viraemia to undetectable levels and usually also the associated systemic immune activation 
(Lichtenstein, 2009). 
ART results in a dramatic restoration of CD4 count to near normal (pre-HIV) levels , however 
there exists a lower-limit threshold of CD4 count, below which the benefits of ART are vastly 
reduced (Jain & Deeks, 2010). The current CD4 count threshold as set by the WHO, is 350 
cells/µl, despite there being a dramatic reduction of non-AIDS conditions (such as 
cardiovascular, liver, and kidney disease) when ART is initiated at even higher CD4 counts 
(Jain & Deeks, 2010). There is a reconstitution of both naïve, and to a lesser extent, memory 
T-cell subsets with the initiation of HAART, which occurs concurrently with a dramatic 
reduction in immune activation (Cotugno, et al., 2012). 
1.3.6.2 Impact of Antiretroviral Therapy on B-cell Function and Distribution 
HAART has been found to reduce HIV-related hypergammaglobulinemia, as well as to 
restore absolute B-cell count and to shift B-cell subset distribution back to pre-HIV status. 
Moir et al. (2008) found that the relative percentages of activated memory, and immature 
transitional B-cells decreased, while those of the resting memory and mature naïve 
increased, 12 months after initiation of HAART, which was similar to the subpopulation 
distribution of HIV-uninfected controls. The same study also found a reduction of apoptosis-
prone activated memory cells. Current data however does indicate that the B-cell 
compartment remains functionally impaired, in spite of HAART (Pensleroso, et al., 2009).  
Protective Ab titers have been found to be deficient, even with successful HAART regimens, 
such that humoral immune responses are severely deficient in such individuals (Cotugno, et 
al., 2012). In spite of the normalization of B-cell subpopulations, there still exists suboptimal 
functionality of B-cells in patients on HAART, especially when there is a delay in its initiation 
(Pensleroso, et al., 2009). The same authors found that when HAART was initiated in acute 
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HIV infection, both the T- and B-cell populations were normalized in terms of both function 
and number compared to matched controls. 
The most notable and important function of B-cells is Ab secretion, one of the key factors in 
humoral immunity. When The B-cell compartment is compromised, which begins to occur 
early in HIV infection before the qualitative and quantitative defects of T-cells are evident, 
there is evidence of defective humoral defense mechanisms (Moir & Fauci, 2013). In this 
sense, if HAART administration is delayed, a state of impaired development occurs, resulting 
in gradual loss of protective Ab titers. With this in mind, especially in vertically-infected 
children, a novel approach in vaccination strategy is needed to maintain protective Ab 
responses in these individuals, although prevention of mother to child transmission (PMTCT) 
programs have effectively eliminated vertical transmission (Pensieroso, et al., 2009; 
Cotugno, et al., 2012).  
Antibodies with the ability to effectively neutralize HIV-1 virions are known to develop at a 
slow pace in most individuals, taking approximately 12 weeks post infection, or longer to 
appear, and even, so only about 20% of infected individuals go on to produce broadly 
neutralizing antibodies 20 to 30 months after initial infection (McMichael, et al., 2010). 
McMichael, et al. (2010) have hypothesized that the delay in broadly neutralizing antibody 
production is due to the profound loss of cell populations crucial to germinal center 
formation, and there is therefore a significant impairment in the capacity for affinity 
maturation, and somatic hypermutation.  
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1.3.7. Novel Markers of B-cell Dysregulation and Potential Therapeutic Targets in HIV-
1 Infection 
In a few recent studies, a large group of inhibitory receptors was found to be expressed on 
B-cell peripheral blood populations, especially so on the tissue-like memory subset 
(exhausted B cells) (Llinàs, et al., 2011). Silva et al. (2011) found that there was significantly 
altered expression of receptors containing ITIM cytoplasmic domains, which are postulated 
to down-regulate BCR-mediated signals. The same authors found that there was a 
significant increase in expression of ITIM-containing receptors, such as FcRL4 (Fc-Receptor 
Like 4, CD307d) and CD85j (Leukocyte Immunoglobulin-like Receptor Subfamily B Member 
1) with untreated HIV-1 infection (Silva et al., 2011).  
Moir, et al. (2008) also identified several potential inhibitory receptors that were expressed 
on tissue-like memory B-cells in HIV-1 infected individuals, which in addition to CD85j and 
FcRL4, included CD72, and CD305, which are also ITIM-containing inhibitory receptors. The 
exact function of many of these markers is unknown, however they are thought to contribute 
towards the exhausted phenotype that exists with chronic HIV-1 infection. These markers 
represent putative therapeutic targets in which it may be possible to down-regulate the 
inhibitory phenotype of the effector cells in chronic HIV-1 infection analogous to PD-1 
blockade in T-cells.  
Therapeutic targets are varied in HIV-1 infection, and for the sake of this thesis we will focus 
on those affecting the B-cell compartment. Vaccination has been established for more than 
200 years, and although most successful vaccines were made without much immunological 
insight, vaccine strategies against HIV-1 have been largely unsuccessful to date (Pulendran 
& Ahmed, 2011). Early efforts in HIV vaccine development were crude, and although 
antibody responses were developed, most strains of HIV were not effectively neutralized 
(Mascola & Montefiori, 2010). The AIDSVAX gp120 vaccine stimulated the production of 
non-neutralising Ab towards HIV Env proteins; while the STEP vaccine was able to stimulate 
a CD8+response, it elicited non-protective effect against the virus; however a recent trial in 
Thailand which utilized a canary pox viral vector expressing gp120, Gag, and Pol, followed 
by AIDSVAX resulted in 30% fewer vaccine-recipients becoming infected with HIV-1 
(McMichales, et al., 2011). Broadly-neutralising antibodies (bNAbs) against HIV have been 
the long-sought after ‘holy grail’ of HIV vaccine research. These bNAbs have been shown to 
neutralise greater than 90% of HIV-1 isolates regardless of their clade (McGuire, et al., 
2014). The main target of these bNAbs is the CD4-binding site (CD4-BS) on HIV gp 120 Env 
glycoprotein, which is normally protected from humoral identification by conformational 
masking and glycan (Zhou, et al., 2010). The most successful of these bNAbs is VRC01, 
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which achieves strong neutralisation of Env in a manner different from that of CD4, where 
there is no conformational changing of Env upon binding (which would hinder further 
neutralisation) (Li, et al., 2011). The main failing point in bNAb generation upon vaccination 
is due to the fact that the vast majority of Env immunogens do not predictably activate B-
cells expressing germline BCRs, a possible reason why only approximately 30% of HIV-1 
infected individuals generate BNAbs (McGuire, et al., 2014). It is clear from this that 
understanding B-cell function, and dysfunction in HIV is crucial to furthering vaccine 
research. 
ART has been shown to decrease systemic hyperactivation concomitantly with suppressed 
viral load, although despite this viral suppression immunologic activation remains higher than 
in uninfected individuals (Cadogan & Dalgleish, 2008). Therefore, intervention strategies that 
limit immune activation, to be used in conjunction with ART are of major importance. 
In the current study a novel potential immunotherapeutic approach of dampening B-cell 
activation and/or inhibiting B-cell apoptosis via the action of VIP, a neuropeptide, was also 
investigated (discussed below). 
1.3.7 Neural-immune Communication and Immunomodulation 
The immune system is organized in a manner, such that different aspects of the immune 
response are controlled from the various organs of the immune system, namely, cellular 
immunity via the thymus and lymph nodes; humoral immunity via the bone marrow and 
spleen; and cells of the innate immune system at environmental contact sites such as the 
skin and mucosa (Thayer & Sternberg, 2010). These anatomical sites are further divided into 
specialized zones and regions where the growth and differentiation of immune cells are 
regulated. 
These anatomical sites, however, do not operate in absolute isolation due to the presence of 
neural pathways that innervate the organs of the immune system (Pozo & Delgado, 2004; 
Fig. 1.5). More specifically, both the autonomic and central nervous (via the hypothalamic 
pituitary-adrenal system) systems play a role in regulation of the immune system, and in turn 
through secretion of soluble mediators like cytokines, feedback loops between the two are 
established (Fig. 1.5, Pozo & Delgado, 2004). 
Vasoactive intestinal peptide (VIP) and pituitary adenylatecyclase-activating polypeptide 
(PACAP) are neuropeptides belonging to the glucagon/secretin family, the former of which 
was initially discovered in the mid-1980s, where it was shown to up-regulate 
adenylatecyclase in a number of tissues (Wiik, et al., 1985). VIP is released both by 
lymphoid innervation (i.e. neural cells in the lymphoid tissue; Fig. 1.5) and directly by T-
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helper type 2 (Th2) cells and regulatory T-cells (Tregs), and thereby promoting Th2 or anti-
inflammatory type response (Pozo & Degado, 2010). The Th2 response results in the 
release of Il-4, IL-5, and IL-10, which are important for IgG1, and IgE synthesis, and 
inhibition of macrophage activation (which leads to a down-regulated cellular immune 
response) respectively (Pozo & Delgado, 2010). VIP is a linear 28 residue neuropeptide that 
acts on two receptors, VPAC1, and VPAC2, both of which belong to the B1 family of G-
protein coupled receptors (GPCR) (Tan, et al., 2014). 
VIP has been shown to down-regulate immune responses and skew responsiveness toward 
a Th2 predominance. It has also been proven to have a cyto-protective effect whereby VIP 
scavenges oxygen radicals (Pozo, et al., 2000). VIP therefore has the potential to modulate 
the chronic inflammation and immune activation that is associated with HIV infection (Pozo, 
et al., 2000). Furthermore, Branch (2011) has shown that the VPAC2 agonist, Helodermin (in 
a dose of 10-9M) was able to inhibit HIV infection via prevention of HIV viral cDNA integration 
into the host DNA. Similarly, Bokaei, et al. (2007) found that a strong resistance to HIV-1 
infection was conferred among Jurkat cells when incubated concurrently with VPAC2-
specific agonists. These authors also found that VPAC2 specific agonists were able to 
directly inhibit the ability of HIV cDNA integration into host DNA.  
Ligation of VPAC2 by VIP has been shown to be a potent inhibitor of activation-induced 
apoptosis in CD4+ T-cells (Delgado & Ganaea, 2006). VIP reduces Fas-Fas ligand 
expression on activated CD4+ T-cells via VPAC2 signaling (Filippatos, et al., 2001). In doing 
so, the authors propose that VPAC2 inhibition of T-cell apoptosis may result in the 
preservation of a pool of memory T-cells with the ability to fight the infection (Filippatos, et 
al., 2001).  
Expression of the VIP receptors, VPAC1 and VPAC2 has been extensively studied in CD4+ 
T-cells using molecular techniques for mRNA expression (Pozo, et al., 2000; Ganea & 
Delgado, 2002; Pozo & Delgado, 2004). T-cells express both VPAC1, and VPAC2, however 
it appears that VPAC1, although constitutively activated, is down-regulated upon stimulation, 
while VPAC2 is expressed at low levels at baseline, and up-regulated with stimulation 
(Ganea & Delgado, 2002). VIP signaling through the VPAC2 receptor has been found to 
have anti-inflammatory downstream effects, and has been implicated in the management of 
both autoimmune, and chronic inflammatory disorders (such as HIV-1 infection) (Pozo & 
Delgado, 2004). Furthermore, VPAC2 expression in untreated HIV infection was found both 
to be upregulated, and positively correlated with Fas-L expression (Ipp, et al., 2014) This 
indicates that therapy targeting VPAC2 would only affect activated cells, and therefore be a 
selective means of inducing an anti-inflammatory state on activated CD4+ T-cells, and further 
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diminishing their propensity towards Fas-mediated apoptosis. Mature B- and T-cells traffic 
to, and reside in the lymph nodes, where sympathetic innervation is present, effectively 
linking the nervous system with the immune system (Huang, et al., 2013). Therefore, if CD4+ 
T-cells have receptors for neurotransmitters such as VIP, it is conceivable that other 
lymphocyte populations, such as CD8+ T-cells, or B-cells would have similar receptor 
expression patterns. To our knowledge, the current study is the first to investigate both 
VPAC2 expression on B-cells, and the effect of VIP on down-regulating aberrant marker 
expression on peripheral blood B-cell subsets.  
The ongoing problems on immune activation associated with both treated, and untreated 
HIV infection has resulted in a large gap in current treatment protocols. The impact of B-cell 
populations with HIV infection has been known for some time, although as mentioned earlier, 
treatment with HAART does not result in complete restoration in their function.  Therefore, 
therapeutic approaches (adjuvant to current protocols) that could limit the effects of immune 
activation on both T-cell and B-cell function would be greatly beneficial.  
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Fig. 1.5. The bidirectional interactions between the immune, and neuroendocrine systems. 
Soluble mediators are released and recognized by both systems, and immune cells and 
neuroendocrine cells share common receptors and even have overlapping functions (Pozo & 
Delgado, 2004) 
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1.4 Aims and Objectives 
1.4.1 Aims 
The primary Aim of this study was to investigate B cell phenotype, subset distribution, and 
activation / exhaustion status in South African untreated chronically HIV-infected individuals 
and uninfected controls, and to relate these findings to clinical markers of disease 
progression. Secondary Aims were: to investigate the expression of the VIP receptor VPAC-
2 on the B-cell population and to evaluate B cell responsiveness in vitro following TLR 
stimulation and, and assess whether VIP can modulate activation-associated marker 
expression. 
 
1.4.2 Objectives 
The objectives of the study were to: 
• Assess the impact of chronic, untreated HIV on B cell subset distribution (transitional, 
naïve, effector, memory) and status (resting, activated, exhausted) and relationship 
with CD4 count, viral load and immune activation (as measured by classic readout 
such as CD38 expression on CD8 T cells)  
• Evaluate expression of traditional markers of B cell activation and 
inhibition/exhaustion (CD70, CD72, CD86, CD38) as well as a selection of less well-
described markers, (CD305, CD300a, CD85j & FCRL4) together with standard 
markers for B cell identification (CD10, CD19, CD20, CD21, CD27) 
• Assess in vitro B cell function following stimulation with TLR ligands (LPS and R848) 
by determining changes in expression of markers of activation (CD70, CD86, CD38), 
and inhibition/exhaustion (CD72, CD85j, CD300a, CD305, FCRL4) 
• Determine expression of VIP receptor VPAC-2 on B cells (ex vivo and following in 
vitro stimulation) 
• Assess ability of VIP to limit B cell activation or apoptosis signaling as measured by 
CD95 expression 
Stellenbosch University  https://scholar.sun.ac.za
 29 
Chapter 2: Methods 
2.1 Patient Cohort 
Twenty-one patients and 18 controls were recruited from the Emavundleni primary health 
care HIV prevention and testing (HPT) clinic in Crossroads, Cape Town (affiliated with the 
Desmond Tutu HIV Centre). The criteria for recruitment of HIV+ve individuals were: age - 21 
years or older; a CD4 count of > 200 cells/µl; ART naïve; and asymptomatic for TB. HIV-ve 
individuals were also 21 years or older, and sourced from the same demographic region, 
thus representative of the racial and socio-economic status of the study subjects. Subjects 
were excluded if they displayed any clinical symptoms of any other infectious-, or non-
communicable diseases. The study was approved by the Human Research Ethics 
Committee (HREC) of Stellenbosch University (HREC N07/09/197). Informed consent was 
obtained from each participant prior to sampling. Blood was drawn from the patients and 
controls into two 10ml Heparin, and one 5ml EDTA, BD Vacutainer® tubes with BD 
Hemogard® lids (Becton Dickenson (BD) Biosciences, San Jose, CA, USA). Samples were 
then couriered to the Division of Medical Virology, Faculty of Medicine and Health Sciences, 
Stellenbosch University within two hours of collection. As this study constituted a sub-study 
of the larger HIV Activation and Inflammation Group (HAIG), there was considerable 
collaboration and cooperation between researchers utilizing the collected blood specimens. 
2.2 CD4 T-cell and CD19 B-cell BD TruCount™ Assays 
CD4 T-cell and CD19 B-cell counts were performed using the EDTA blood sample via 
standard stain-lyse-no wash BD MultitestTM and TriTestTM protocols. MultitestTM CD3-
FITC/CD8-PE/CD45-PerCP/CD4-APC reagent was used for the CD4 T-cell counts, and 
TriTestTMCD3-FITC/CD19-PE/CD45-PerCP reagent was used for the CD19 count (both 
Becton Dickenson (BD) Biosciences). BD Trucount tubes (BD Biosciences) were used in 
both assays. Trucount tubes were labeled according to HIV group and number (Control HIV-
ve:“N100” or HIV+ve:“P100”, etc.). Twenty µl of Multitest antibody cocktail (for CD4 Trucount) 
or Tritest (for CD19 Trucount) was then pipetted into the bottom of the tube above the steel 
retainer and bead pellet. Fifty µl EDTA blood was then added to the tube which was 
subsequently vortexed, and then incubated for 15 minutes in the dark at room temperature. 
After incubation, 450µL of 1:10 diluted FACSlyse™ solution (BD Biosciences) was added 
and the tubes vortexed again, and allowed to incubate for 15 minutes in the dark at room 
temperature. The samples were then analyzed on the flow cytometer (BD FACSCalibur with 
MultiSET™ software). This CD4 count method is the manufacturer-recommended SOP used 
in the Division of Medical Virology, Faculty of Health Sciences, Stellenbosch University, and 
is South African national accreditation system (SANAS)-accredited. 
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2.3 HIV Viral Load 
Two ml of EDTA blood was centrifuged at 20°C at 300g (Jouan CR422, Thermo Fisher 
Scientific Inc., Waltham, MA, USA) for 12 minutes at room temperature with the brake off. 
Approximately 1ml of plasma was then decanted into a 1.7ml Axygen microcentrifuge tube 
(Axygen, Inc., Union City, CA, USA) and the sample was sent for viral load testing using the 
NucliSensEasyQ® HIV-1 v1.2 Viral Load Test (BioMerieux Inc., Boxtel, Netherlands). This is 
an HIV-1 RNA quantitative assay that monitors viral load by applying NASBA technology 
combined with detection of real-time molecular beacons, and has a detection range of 350 to 
106 copies/ml. This is the routine method for viral load testing in the Division of Medical 
Virology, Faculty of Health Sciences, Stellenbosch University, and is SANAS-accredited. 
2.4 Four Colour Flow Cytometry for CD38 Expression on CD8+ T-cells 
A 50µl aliquot of EDTA whole blood underwent a stain-lyse-wash protocol for determination 
of CD38 expression on CD8+ T-cells via flow cytometry (BD FACSCalibur). Pre-optimised 
volumes of CD3-FITC, CD8-PerCP, CD38-APC (BD Biosciences), and PD-1-PE (Biolegend) 
were added to a 5ml falcon tube (BD Biosciences) containing 50µl EDTA whole blood and 
allowed to incubate for 15 min at room temperature in the dark. Following this, 500µl 10x 
FACSLyse™ solution (BD Biosciences) was added to the tube and allowed to incubate for a 
further 15 minutes in the same conditions as before. Thereafter, 500µl of phosphate-buffered 
saline (PBS) containg 2% heat inactivated foetal calf serum (FCS, Gibco®, Life 
Technologies, Carlsbad CA, USA) was added to the tube, which was subsequently 
centrifuged at 300g for 5 minutes at room temperature (Jouan CR422). The supernatant was 
discarded, and the pellet resuspended in 500µl PBS containing 1% paraformaldehyde 
fixative. The tubes were kept at 4°C in the dark until acquired within 24 hours on a BD 
FACSCalibur flow cytometer and analysed using CellQuest Pro software.  
A dotplot of forward scatter (FSC) vs. side scatter (SSC) was drawn, and a gate was set 
around the lymphocyte region (R2, Fig. 2.1 A). A plot of CD3-FITC vs. SSC was used to gate 
on 10 000 T-cells (R3, Fig. 2.1 B). Secondary plots of CD38-APC vs. CD8-PerCP, and PD-1-
PE vs. CD8-PerCP were drawn using the CD3 gate (R3) to assess the CD3+CD8+CD38+ 
(Fig. 2.1 C), and CD3+CD8+PD-1+ (Fig. 2.1 D) populations.  
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A B 
C D 
Fig. 2.1 Gating strategy for CD38 expression on CD8 T-cells. A) A gate was drawn around 
the lymphocyte region on a dotplot of FSC vs. SSC (R2). B) These cells were then interrogated 
on a dotplot of CD3 vs. SSC, where a gate was drawn around the CD3+ population (R3), of 
which 10000 events were acquired. C) A plot of CD38 vs. CD8 was drawn, and displayed only 
the CD3+ events. D) Similarly a plot of PD-1 vs. CD8 was drawn which displayed only the CD3+ 
events. 
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2.5 B-cell Enrichment for functional studies 
B-cells were isolated for culture and stimulation using RosetteSep™ Human B-cell 
enrichment cocktail and Ficoll-Paque™ density gradient centrifugation (Stemcell 
technologies, Vancouver, British Columbia, Canada). 8ml of Heparinised whole blood was 
added to a 50ml centrifuge tube (Falcon, BD Biosciences) containing 400µl RosetteSep™ 
Human B-cell enrichment cocktail (Stemcell technologies) and allowed to incubate for 20 min 
at room temperature in the dark. After incubation, the whole blood solution was diluted with 
an equal quantity of PBS containing 2% heat inactivated FCS (Gibco®), and the resulting 
mixture was layered on top of 15ml Ficoll-Paque™ (Stemcell technologies) in a 50ml 
centrifuge tube (Falcon, BD Bioscience). The tube was then centrifuged at 1200g for 20 
minutes at room temperature with the brake off (Jouan CR422), resulting in the enrichment 
of the B-cell population at the plasma-Ficoll interface. These cells were carefully aspirated 
off the plasma-Ficoll-Paque™ interface and placed in a 50ml centrifuge tube (BD 
Bioscience), to which an equal volume of RPMI 1640 (Gibco®, Life Technologies) containing 
5% FCS (Gibco®, Life Technologies), was added. This tube was then centrifuged at 300g 
for 5 minutes at room temperature with the brake off. Following centrifugation, the 
supernatant was discarded, and the cells were re-suspended in 1ml RPMI-1640 (Gibco®, 
Life Technologies) containing 5% FCS (Gibco®, Life Technologies).  
Cell count was performed by use of a Neubauer Haemocytometer (Hausser Scientific, 
Horsham, PA, USA). A 50µl sliquot of cell suspension was added to 50µl of Turk’s solution 
(Sigma-Aldrich, St. Louis, MO, USA) and allowed to stand for 1 minute. A glass slide cover 
was placed on the haemocytometer and approximatedly 10µl of stained cell suspension was 
pipetted under the slide cover. Cells were counted, after which the volume of the 1ml cell 
suspension was adjusted to a final concentration of 5x105 cells/ml. Purity was measured via 
flow cytometry (panel 6, see table 2.1), to determine whether any significant amounts of 
contaminating T-cells (CD45+CD3+) were remaining after enrichment. 
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Table 2.1: List of Antibody Panels used in this study.  
The optimal volume of each antibody was calculated by means of titration experiments, and 
calculated staining index. Backbone antibodies are CD19-AmCyan, CD21-APC, CD27-
PerCp-Cy5.5, and CD10-APC-Cy7. Intracellular fluorochromes are indicated by *. Panels 1 -
6 were run on a BD FACSCanto II, and panel 7 was run on a BD FACSCalibur. 
Panel # FITC PE APC PerCP-
Cy5.5 
PE-Cy7 APC-
Cy7 
Pacific 
Blue 
AmCyan 
1: Activation CD70 CD126 CD21 CD27 CD38 CD10 CD25 CD19 
2: Activation/Inhibition CD72 CD305 CD21 CD27 CD38 CD10 CD86 CD19 
3: Inhibition/Apoptosis CD85j CD300a CD21 CD27 CD307d CD10 CD95 CD19 
4: TLR/Exhaustion CD287* CD284 CD21 CD27 CD307d CD10 CD86 CD19 
5: VPAC  VPAC 1 CD21 VPAC2    CD19 
6:Purity CD3 CD19  CD45     
7: CD38/8  CD3 PD-1 CD38 CD8 
(PerCP) 
    
 
2.6 B-cell Culture  
Ninety-six-well plates were set up as per Fig. 2.2: 1 well per stimulant (including 
unstimulated), per flow cytometry staining panel (1 to 5, Table 2.1), per patient, and a single 
well per patient of panel 6 (Purity). The cells were cultured in an incubator for 18 hours in the 
following conditions: 37°C, 95% humidity, 5% CO2.(Nuaire). Isolated cells were assessed for 
purity directly after enrichment, via flow cytometry. Panel 6 (Purity pane, Table 2.1l) 
contained CD3-FITC, CD19-PE and CD45-PerCP, which allows for detection of presence of 
contaminating T-cells based on both CD3 and CD45 expression. The negative 
selection/enrichment procedure employed resulted in an average of 80% purity, consistent 
with the product literature (StemCell Technologies). Cells were also assessed for viability 
before and after culture for 18 hours using Trypan Blue solution (Sigma-Aldrich) with the 
TLR ligands/agonists and/or VIP. There was also an unstimulated control to which the 
stimulant conditions were compared. Less than 1% of cells stained positive for Trypan blue 
before and after incubation for 18 hours. 
 
2.6.1 B-cell Stimulation with LPS and R848 
A total of 5 x104 enriched B-cells (i.e. 100µl of adjusted cell preparation) were added to a 
well of a round bottomed tissue culture 96-well plate (Falcon, BD Bioscience). Into each well, 
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Gibco® RPMI-1640 (Life Technologies) containing 5% FCS (Gibco®, Life Technologies) and 
either 0.1µg/ml LPS (TLR4 ligand) or 0.1µg/ml R848 (an imidazoquinoline compound, which 
stimulates TLR7/8) (both Invivogen, San Diego, CA, USA), was added (final volume of each 
well was adjusted to 200µl). RPMI-1640 (Gibco® Life Technologies) containing 5% FCS 
(Gibco®, Life Technologies) in the same volume as the TLR stimulant was used in the 
unstimulated wells. The optimal concentration of both LPS and R848 was based on the 
product literature, and further confirmed via a dose- and time-optimising assay performed on 
isolated B-cells of healthy donors incubated at 37°C, 95% humidity, 5% CO2 for a specified 
time period (Nuaire, Plymouth, MN, USA). Time-dose combinations included 18h, 24h, 48h, 
and 0.01µg/ml, 0.1µg/ml, and 1.0µg/ml). Responsiveness to stimulation was assessed via 
flow cytometric evaluation of expression of the activation markers in panel 1 (Table 2.1) 
relative to the unstimulated state. Unstimulated matched controls were run at each time 
point. 
2.6.2 B-cell inhibition with VIP  
Twelve samples each of the HIV+ve and HIV-ve groups underwent inhibition with VIP, 
however 4 HIV+ve samples were excluded due to low CD4 counts (<200 cells/µL) and 
undetectable viral loads, leaving the total number of VIP-inhibited samples at 8 HIV+ve and 
12 HIV-ve. Cells were co-incubated (hereafter known as ‘inhibited’) with 10-8M VIP and 
0.1µg/ml of either R848 or LPS per 5x104 cells (See Fig. 2.2). The optimal concentration of 
VIP was based on the findings of Bokaei, et al. (2007), and also confirmed by other 
members of our laboratory on CD4+ lymphocytes and monocytes. Time- and dose- (18h, 
24h, 48h, and 10-7M, 10-8M, 10-9M) optimizing assays were also performed on isolated B-
cells of healthy donors to determine the optimal concentration of VIP and time of culture for 
B-cells. Culture response to VIP inhibition was measured via flow cytometry for VPAC-2 
expression relative to baseline (i.e. uninhibited) controls, run at each time point. This data 
was used concurrently with viability determination via Trypan Blue (Sigma-Aldrich) staining 
at each time point, and live/dead discrimination under light microscopy (Olympus) on a 
Neubauer Haemocytometer (Hausser Scientific). The viability of the inhibited cells at each 
time point was compared to that of the control cells, where viability was consistently ≥ 90%. 
Viability of the inhibited cells did not differ from that of the controls by more than 5%. 
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Fig.2.2. Schematic of 96-well plate showing the layout of the unstimulated, stimulated, and 
VIP-inhibited cells respectively. Each well represents a separate culture condition and panel. The 
‘viability’ well (G4) was unstimulated and underwent Trypan Blue staining to determine the number of 
cells that may have died during the 18h of culture. 
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2.7 Flow Cytometry Assay Optimisation 
2.7.1 Antibody titrations 
Antibody titrations were performed in order to determine the most efficient quantity of each 
antibody for optimal staining, with minimal wastage of unbound antibody (Lamoreaux, 
Roederer, & Koup, 2006). Staining index (see below) was determined for each antibody in 
isolation and was performed whenever a different batch of antibody was used for the first 
time in a panel. The recommended amount of antibody was added to a 5ml Falcon® tube 
(BD Biosciences), followed by 50µl of whole blood, and allowed to incubate at room 
temperature for 15 minutes in the dark. Following this, 500µl of 10x diluted FACSLyse (BD 
Biosciences) was added to each tube, which was then allowed to incubate for a further 15 
minutes in the dark at room temperature. Following this, 500µl of PBS containing 2% FCS 
was added to each tube, which was then centrifuged at 300g for 5 minutes at room 
temperature (Jouan CR422). The supernatant was then discarded, and the pellet was 
resuspended in 350µl of PBS containing 2% FCS. The same procedure was performed 
using doubling dilution titrations of the recommended antibody volume (i.e. 1/2 
recommended volume, 1/4 recommended volume, 1/8 recommended volume).  
Staining index is a metric that is calculated by the separation of a positively stained and 
negatively stained population, and is determined by taking the mean fluorescence intensity 
(MFI) of the negative population (MFINeg, Fig. 2.3a), and dividing it by the difference in MFIs 
between the two populations (D, Fig. 2.3a). Alternatively, one can also calculate the staining 
index by dividing MFIPos by MFINeg, which will give similar results. The optimal 
concentration/volume of monoclonal antibody was determined by the saturation point (Fig. 
2.3b), which is the point where there was the most efficient separation of the positive and 
negative populations. 
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Fig. 2.3. Schematic overview of Staining Index .A) D refers to the difference in mean fluorescent 
intensity of the negative population (MFINegin black), and the positive population (MFIPos in red). 
Staining index may either be calculated as MFINeg/D, or MFIPos/MFINeg. B) Graph of staining indices 
for titrated concentrations of monoclonal antibody. The saturation point is indicated on the graph, 
which is the point at which there is optimal separation of the positive and negative populations. There 
is a rise in the curve due to the increase in signal-to-background ratio, which is a decrease in “D”, and 
a bright negative population. Adapted from Lamoreaux, Roederer, &Koup, (2006). 
A B
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2.7.2 Compensation for fluorochrome spillover between detectors 
Spectral overlap is a phenomenon that occurs in flow cytometry, whereby the fluorescence 
emitted by a fluorochrome (e,g. PE) is picked-up by a detector other than the appropriate 
one (e.g. the FITC detector). This is due the spectral emission of certain fluorochromes 
overlapping. Compensation was therefore performed on a monthly basis to adjust for 
spectral overlap between fluorochromes, and performed according to the manufacturer’s 
specifications (BD Biosciences, 2013). The titrated quantity of monoclonal antibody was 
added to a 5ml Falcon™ tube, followed by 1 drop of the BD Positive CompBeads. The 
antibody CompBead mix was then gently vortexed, and allowed to incubate for 15 minutes 
at room temperature in the dark. 1ml of PBS containing 5% FCS (Gibco, Life Technologies) 
was then added to the sample, which was then centrifuged at 200g for 5 minutes. The 
supernatant was discarded, and then 1 drop of the BD Negative CompBeads was added to 
the tube, followed by 1ml of PBS containing 5% FCS (Gibco, Life Technologies), and gently 
vortexed. Compensation was performed using a semi-automated procedure on the BD 
FACSCanto II (BD Biosciences), according to manufacturer’s specifications. Compensation 
settings were copied across for each experiment for the month, and only re-run if the QC 
checks (section 2.7.4) failed despite having followed troubleshooting steps.  
2.7.3 Determination of true population negativity via FMO 
Fluorescence minus one (FMO) is a means of determining the cutoff for positivity in flow 
cytometry. The principle of the test is to have a tube set up as if you were running an 
experiment, except that the tube contains all except for one fluorochrome (Macker & Trotter, 
2006). This is especially useful for markers whose expression is unknown. It is also of value 
when comparing separate conditions in stimulation assays. FMOs are also useful to ensure 
minimal spillover and to eliminate autofluorescence. FMOs, and compensation controls were 
run each time the flow cytometer was serviced or if a new batch of antibody was used 
(section 2.7.2.). 
2.7.4 Daily and weekly QC of the FACSCanto II 
Experimental voltages were set according to compensation controls; however, these 
voltages were adjusted according to the daily and monthly voltage baseline QC (quality 
control) checks. These checks were performed in order to optimize the colour compensation 
settings, and were specifically designed for use with tandem dye conjugates. Daily and 
monthly checks were performed through the Cytometer Setup & Tracking (CS&T) application 
(part of the FACSCanto II software, FACSDiva), using BD CS&T beads (BD Biosciences). 
The CS&T application also monitors instrument performance over time, via Levey-Jennings 
plots, and alerts the user when any of the detectors are performing outside their desired 
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range. “CS&T Performance” was run daily, while “CS&T Baseline” was run on a monthly 
basis. These QC checks allowed the FACSCanto II settings to be standardized to a certain 
level/norm, across different days, as well as across different FACSCanto IIs. It is important 
to note that if the CS&T application passed, then the compensation settings were likely to 
have been unaffected. It is only when the baseline CS&T application was run, that 
compensation controls were re-run, or if the daily CS&T performance failed repeatedly, 
despite having followed troubleshooting steps. Daily experiments were, however run on the 
cytometer settings from the compensation protocol, while the CS&T application was merely 
used to determine cytometer reliability. 
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Table 2.2: List of Antibody manufacturers and clones. All antibodies were mouse anti-
human.  
 Function Vol  Fluorochrome Clone Isotype Manufacturer 
Tritest CD3/CD19/CD45 for enumerating B-cells 20µl FITC SK7/SJ25
C1/2D1 
IgG1, κ BD Biosciences  
CD3 T-cell receptor 10µl FITC SK7 IgG1, κ BD Biosceinces 
CD8 T-cell subset marker 10µl PerCP SK1 IgG1, κ BD Biosciences 
CD10 Neprilysin, expressed on B-cell precurors 5µl APC-Cy7 HI10a IgG1, κ Biolegend  
CD19 Pan B-cell marker  5µl AmCyan SJ25C1 IgG1, κ BD Biosciences  
CD21 Complement receptor 2 5µl APC B-Ly4 IgG1, κ BD Biosciences  
CD25 IL-2 receptor α-chain 5µl Pacific Blue BC96 IgG1, κ Biolegend  
CD27 TNF superfamily receptor, marker of B-cell 
memory 
2.5µl PerCP-Cy5.5 O323 IgG1, κ Biolegend  
CD38 Cyclic ADP ribose hydrolase 5µl PE-Cy7|APC LS198-4-3 IgG1, κ Beckman Coulter 
|BD 
CD70 Activation marker, ligand for CD27 5µl FITC Ki-24 IgG3, κ BD Biosciences  
CD72 Inhibitory receptor, ligand for CD5 5µl FITC J4-117 IgG2b, κ BD Biosciences  
CD85j Inhibitory receptor which down-regulates 
activation of APCs 
5µl FITC GH1/75 IgG2b, κ BD Biosciences  
CD86 B7.2, upregulated upon activation, ligand 
for CD28 
2.5µl Pacific Blue IT2.2 IgG2b, κ Biolegend  
CD95 FAS receptor, indicative of apoptosis 
signaling 
2.5µl Pacific Blue DX2 IgG1, κ Biolegend  
CD126 IL-6 receptor 5µl PE M5 IgG1, κ BD Biosciences  
CD279 Programmed cell death 1 (PD-1) 5µl PE EH12.2H7 IgG1, κ Biolegend 
CD284 Toll-Like Receptor 4, recognizes LPS 5µl PE HTA125 IgG2a, κ Biolegend  
CD287 Toll-Like Receptor 7, intracellular receptor, 
recognizes ssRNA 
2.5µl FITC 533707 IgG2a, κ R&D Systems 
CD300a Inhibitory receptor, implicated as a 
receptor for phosphatidylserine 
5µl PE E59.126 IgG1, κ Beckman Coulter 
CD305 LAIR-1, an inhibitory Ig-like receptor, 
implicated as a collagen receptor 
5µl PE DX26 IgG1, κ BD Biosciences  
CD307d FcRL4, an inhibitory Fc-like receptor found 
on exhausted B-cells 
5µl FITC 413D12 IgG2b, κ Biolegend  
VPAC1 Receptor for VIP, constitutively expressed 10µl FITC SP234 IgG1, κ Santa Cruz 
VPAC2 Receptor for VIP, upreg upon activation 10µl PerCP SP235 IgG1, κ Conjug. in house 
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2.8 Multi-parameter Flow Cytometry of Whole Blood for Ex Vivo 
Phenotyping (Characterisation of Markers of Activation, Inhibition And 
Exhaustion) 
2.8.1 Sample Preparation 
One-hundred µl of Heparinised whole blood was added to a 5ml falcon tube (BD 
Biosciences) containing a cocktail of up to 8 monoclonal antibodies, each conjugated to a 
different fluorochrome (The same panels were used for both the whole blood, and isolated 
cell assays Table 2.1). The tubes were allowed to incubate for 15 minutes in the dark at 
room temperature, after which, 1ml of 10x diluted FACSLyse (BD Biosciences) was added to 
each tube, which was then allowed to incubate for a further 15 minutes in the dark at room 
temperature. Following this, 500µl of PBS containing 2% FCS was added to each tube, 
which was then centrifuged (Jouan CR422) at 300g for 5 minutes at room temperature. The 
supernatant was then discarded, and the pellet was resuspended in 350µl of PBS containing 
2% FCS. The tubes were stored in the dark at 4°C until they were read on a FACSCanto II 
flow cytometer (BD Biosciences). This same procedure was followed for the determining 
CD38 expression on CD8+ T-cells (CD3-FITC, CD8-PerCP, CD38-APC, PD-1-PE), except 
these samples were acquired on a BD FACSCalibur (BD Biosciences). 
2.8.2 Gating Strategy 
All cells were initially gated on FSC-area versus FSC-height to discriminate between the 
single cells populations, and doublets (Fig. 2.5a). Cells were then gated on CD19-AmCyan 
(BD Biosciences) versus SSC-area (Fig. 2.5b) to elucidate the CD19+ population. A dotplot 
of FSC versus SSC (Fig. 2.5c) was drawn to see whether the cells in P2 fell into the 
lymphocyte area. [This is known as back-gating, and it is used as a cross-check mechanism 
in multi-parameter flow cytometry, allowing cell populations to be visualized in multiple 
different gated populations]. A maximum of 10 000 CD19+ events were acquired in the B-cell 
gate, or the sample was run for 5 minutes.  
The B-cells were further subdivided into their respective sub-populations (Fig. 2.5d) in a 
dotplot of CD21-APC (BD Biosciences) versus CD27 PerCP-Cy5.5 (Biolegend), namely 
resting memory (RMem), activated memory (AMem), naïve (N), and Tissue-Like Memory 
(TLMem). Transitional (TR) B-cells were gated on CD10-APC-Cy7 (Biolegend) versus 
CD19-AmCyan. Plasmablasts were elucidated in panels 1 and 2 in a dotplot of CD27-
PerCP-Cy5.5 versus CD38 PE-Cy7 (Beckman Coulter) (Fig. 2.5e). Each subset was then 
investigated for expression of the activation, inhibitory, or exhaustive markers, per B-cell 
subset, excluding TR B-cells, which were only enumerated. Positive expression cut-off of 
each marker was determined by FMO (See section 2.7.3). 
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2.9 Multi-parameter Flow Cytometry of Isolated B-cells for Functional 
Characterisation of Markers of Activation, Inhibition, and Exhaustion 
2.9.1 Sample Preparation 
Following 18 hours of culture, the 96-well plates were centrifuged at 300g for 5 minutes at 
room temperature (Jouan CR422). The supernatant was discarded and 200µl PBS 
containing 2% FCS was added to each well, after which the pellet was gently agitated. The 
plates were centrifuged again in the same conditions, after which the supernatant was 
discarded and 200µl PBS containing 2% FCS was added to each well, and the pellet was 
gently agitated. The content of each well was then transferred to separate 5ml Falcon tubes 
(BD Biosciences) to which the appropriate antibody cocktail was added (See section 2.7.1 
for details on Ab titrations). This was allowed to incubate for 15 minutes at room temperature 
in the dark. Thereafter, 200µl PBS containing 2% FCS was added to each of the tubes, 
which were then centrifuged at 300g for 5 minutes at room temperature. The supernatant 
was then discarded, and the cells were resuspended in 350µl PBS containing 2% FCS, and 
the stored in the dark at 4°C for a maximum of 2 hours until they were read on a FACSCanto 
II flow cytometer (BD Biosciences). If the FACSCanto II was unavailable for direct analysis, 
samples were fixed using BD Stabilising Fixative (BD Bioscience), which preserves cells and 
prevents tandem dyes (such as APC-Cy7) from degrading.  
Following this, panel 4 of each sample then underwent intracellular staining for CD287. 
Here, 250µl BD CytofixCytoperm™ (BD Biosciences) was added to each tube in panel 4 
instead of 350µl PBS containing 2% FCS, and the sample was incubated in the dark at 4°C 
for 30 minutes. Thereafter, 500µl 10x diluted BD PermWash™ was added to the sample, 
which was then centrifuged at 300g for 5 minutes at 4°C. The supernatant was subsequently 
discarded, and a further 300µl 10x diluted BD PermWash™ was added to the sample to 
resuspend the cell pellet. The appropriate quantity of intracellular fluorochrome (Table 2.1) 
was added to the tubes, which were further incubated at 4°C for 20 minutes. The tubes were 
then centrifuged at 300g for 5 minutes at 4°C, following which their supernatant was 
discarded. The cells were then resuspended in 350µl PBS containing 2% FCS and stored in 
the dark at 4°C until they were read on a FACSCanto II flow cytometer (BD Biosciences). 
2.9.2 Gating Strategy 
Isolated cells were initially gated on FSC-area versus FSC-height to discriminate between 
the single cells populations, and doublets (Fig. 2.6a). A maximum of 10 000 B-cells were 
then gated on CD19-AmCyan (BD Biosciences) versus SSC-area (Fig. 2.6b) to elucidate the 
CD19+ population. A plot of FSC vs. SSC was used to determine whether the B-cells fell 
within the predictable lymphocyte area (Back gating) The B-cells were further subdivided into 
Stellenbosch University  https://scholar.sun.ac.za
 43 
their respective sub-populations (Fig. 2.6d) in a dotplot of CD21-APC (BD Biosciences) 
versus CD27-PerCP-Cy5.5 (Biolegend) (as shown in panel 1 dotplot D below), namely 
RMem, AMem, N, and TLMem. TR B-cells were gated on CD10-APC-Cy7 (Biolegend) 
versus CD21-APC. Plasmablasts were elucidated in panels 1 and 2 in a dotplot of CD27-
PerCP-Cy5.5 versus CD38 PE-Cy7 (Beckman Coulter) (Fig. 2.6e). 
 
2.10 Statistical Analyses 
Statistical analyses were performed using GraphPad Prism software (Version 5, GraphPad 
Software, San Diego, California, USA). Due to the complexity of the gating strategy, which 
involved multiple gates and Boolean logic to elucidate all the relevant subpopulations, some 
subpopulation events were not excluded from the rest resulting in combined subset %s 
adding up to a total percentage > 100% (maximum was 105). We corrected for this by 
calculating the ratio out of 100, i.e. where the sum of the subpopulations was 105, and the % 
MN was 52.5%, then we multiplied the %MN by the correction factor (correction factor: 
100/105=0.9523). Therefore, the corrected %MN was 50%. Where % increase or decrease 
was described, the value from the second condition was subtracted from that of the first, and 
the result divided by the value of the first condition, which was then multiplied by 100. 
Therefore if expression was 20% at baseline, and 60% with stimulation, then % increase 
was (60-20)/20, which is a 200% increase.  
Where two parameters were compared with one another, an unpaired T-test was used due 
to the fact that most of the data was normally distributed (as calculated by the Shapiro-Wilk 
test for normality), where stated a Mann-Whitney U test was performed for non-parametric 
data. This method was primarily used when comparing the same parameter between the 
experimental and control groups. For multiple comparisons within e.g. unstimulated vs. 
stimulated cells in the same experimental group (either HIV+, or HIV-), a repeated measures 
one-way Analysis of Variance (ANOVA) was used, and if the data was non-parametric, a 
Friedman test was performed. These analyses were then followed by either of the following 
posttests; a Dunn’s multiple comparison test for non-parametric data, or a Bonferroni’s 
multiple comparison test for parametric data. Multiple correlations were performed using a 
Spearman’s rank correlation test. Data are reported as mean percentage ±SD (Standard 
deviation) expression unless otherwise stated. Significance levels were set at p<0.05, while 
any p-value >0.05 is reported as non-significant “ns”. Percentage inhibition was calculated 
by dividing the difference in percentage expression before and after inhibition, by the 
percentage expression before inhibition. Percentage expression was determined by dividing 
the number of positive events by the number of events in each subset. A biostatistician was 
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consulted to ensure that all statistical analyses performed were appropriate to the data set. 
Box and whisker plots were drawn using GraphPad Prism software, where the median is 
represented by a vertical line through the box, and the mean is represented by a “+” within 
the box. The whiskers were drawn according to the Tukey method, where the upper whisker 
stops at the data point that is largest value less than the sum of the 75th percentile plus 1.5 
times the interquartile range (IQR). Any data points above this were plotted as individual 
points. Similarly, the bottom whisker stops at the data point that is the lowest value greater 
than the 25th percentile minus 1.5 IQR, and any points less than this value were plotted as 
individual data points (GraphPad Software, 2014). 
Fig. 2.4 Schematic overview of data analysis. The results of this study were divided into two main 
subsections, namely the ex vivo whole blood data, and the overnight cultured isolated B-cells. We first 
compared subset distribution within that of the ex vivo data (i.e. between HIV+ve and HIV-ve), then 
followed by the phenotypic marker expression in the same manner. Next, the ex vivo subset 
distribution was compared with that of the unstimulated cultured B-cells, which was then compared 
with the different isolated B-cell culture states. Thereafter Phenotypic marker expression was 
investigated between the different culture conditions within the HIV+ve group, and also between the 
two groups in the same condition (i.e. unstimulated CD38 on Activated Memory cells between the 
HIV+ve and HIV-v groups). See section 2.12 for details on statistical analysis 
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Figure 2.5: Whole blood gating strategy. A) Cells were initially gated on FSC-A vs. FSC-
H to obtain singlet and live cells in gate ‘P1’. B) These cells were then gated according to 
CD19-AmCyan vs. SSC-A to obtain the total B-cell population in gate ‘P2’. C) Gate ‘P2 
AND P3’ was used to ensure that all cells used for further analysis were B-cells. D) Cells 
from ‘P2 AND P3’ were plotted on CD21-APC vs. CD27-PerCP-Cy5.5 to visualize the 
activated, resting, and tissue-like memory cells, and mature naïve B-cells. E) Plasmablasts 
were gated on CD38-PE-Cy7 vs. CD27-PerCP-Cy5.5, and these cells, which would 
otherwise show up in the ‘AMem” quadrant of the previous plot, were separated via the 
gate ‘AMem AND NOT Plasmablasts’. F) Transitional B-cells were gated on CD21-APC vs. 
CD10-APC-Cy7 from the ‘TLMem’ quadrant (i.e. CD21-CD10+. Q2-1 & Q4-1 contained no 
cells)  
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Figure 2.6: Isolated-cell gating strategy. A) Cells were initially gated on FSC-A vs. FSC-H to 
obtain singlet and live cells in gate ‘P1’. B) These cells were then gated according to CD19-
AmCyan vs. SSC-A to obtain the total B-cell population in gate ‘P2’. C) Gate ‘P2 AND P3’ was 
used to ensure that all cells used for further analysis were B-cells. D) Cells from ‘P2 AND P3’ 
were plotted on CD21-APC vs. CD27-PerCP-Cy5.5 to visualize the activated, resting, and 
tissue-like memory cells, and mature naïve B-cells. E) Plasmablasts were gated on CD38-PE-
Cy7 vs. CD27-PerCP-Cy5.5, and these cells, which would otherwise show up in the ‘AMem” 
quadrant of the previous plot, were separated via the gate ‘AMem AND NOT Plasmablasts’. F) 
Transitional B-cells were gated on CD21-APC vs. CD10-APC-Cy7 from the ‘TLMem’ quadrant 
(i.e. CD21-CD10+. Q2-1 & Q4-1 contained no cells) 
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Chapter 3 Results 
The current study examined the phenotypic and functional properties of B cells in chronically 
HIV-1 infected individuals and healthy controls. The ultimate goal was to ascertain whether B 
cells in South African infected individuals were substantially affected by HIV-1 infection, even 
when CD4 count was relatively stable and participants were asymptomatic. The study 
assessed total B cells and B cell subsets in both study groups with regard their absolute 
numbers and distribution and phenotypic characteristics. A focus throughout was how 
immune activation (as determined by CD38 expression on CD8+ T-cells) was related to 
changes in the B-cell compartment. Following on from the ex vivo characterization, we also 
assessed functional responsiveness of B cells to TLR-mediated stimulation (LPS and R848) 
to ascertain whether chronic HIV-1 impacted on B-cell function. Finally we examined the 
VIP-VPAC ligand-receptor pathways as a potential therapeutic target for modulating aberrant 
B cell responses 
Expression of markers of activation, inhibition, and exhaustion was measured on each B-cell 
subset, as well as on the total B-cell population in both study groups. For the ex vivo subset 
characterization and phenotyping component, single expression of each marker on each 
individual subset and total B cells was analysed, and data from the 21 HIV+ve samples was 
compared to that of the 18 HIV-ve control group samples. For the majority of the stimulatory 
and inhibitory data that is presented graphically, only the HIV+ve group was plotted. In the 
isolation and stimulation component of this study, in vitro marker expression was also 
assessed per subset between the HIV+ve group and HIV-ve control, in each of the 
stimulation conditions (LPS and R848). Stimulation experiments were performed with/without 
VIP to assess the modulatory capacity of VIP on B-cells. Co-expression of certain markers 
was investigated in this study; however the results presented below are restricted to single 
marker expression to avoid over-complicating a large data set. Furthermore, only significant 
data is presented in figures for the same reason. Twelve samples each of the HIV+ve and 
HIV-ve groups underwent inhibition with VIP, however 4 HIV+ve samples were excluded due 
to low CD4 counts (<200 cells/µL) and undetectable viral loads, leaving the total number of 
VIP-inhibited samples at 8 HIV+ve and 12 HIV-ve, so one might expect to find greater 
statistical significance with higher sample numbers. 
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3.1. Subset Distribution 
3.1 Ex vivo subset distribution 
A brief summary of the study cohort demographic is presented in Table 3.1. The mean 
absolute B-cell count as determined by Trucount assay (BD Biosciences) was significantly 
decreased in the HIV+ve group (188.6 ± 181.3 vs. 276.8 ± 141.8 cells/µL, p=0.0002, Fig. 3.1 
B). CD4 count was decreased with HIV (472.3 ± 237.5 vs. 819.9 ± 275.4; p<0.0001, Fig. 3.1 
A) as expected, while the proportion of CD8+T-cells co-expressing CD38 was increased with 
HIV infection (46.25 ± 22.94 vs. 28.33 ±17.95; p<0.0001, Fig. 3.1 C).  
 
Table 3.1. Summary of patient demographics. Data represented as mean ± standard 
deviation (SD). ns-not significant, significant data indicated in bold. 
 
 
The relative percentage of resting memory cells was significantly decreased in the HIV+ve 
group, with a mean percentage of 17.78 ± 7.54% of total B-cells compared to 26.33 ± 8.65% 
in the HIV-ve control (p=0.0097), while the relative percentage of the tissue-like memory cell 
phenotype was increased in the HIV+ve group (24.57 ± 14.84% vs. 15.43 ± 10.39%, 
p=0.0314). The relative percentages of plasmablasts, transitional B-cells, mature naïve, and 
activated memory B-cells were not significantly different between the HIV+ve group and the 
HIV-ve control (Fig. 3.3).  
The percentage tissue-like memory cells in the HIV+ve group ex vivo correlated negatively 
with percentages of resting memory and mature naïve B-cells (r=-0.4844, p=0.026, Fig. 3.4 
C; r=-0.7795, p<0.0001, Fig. 3.4 A), and also positively with the percentage of activated 
memory cells (r=0.6532, p=0.0013, Fig. 3.4 E). The percentage mature naïve B-cells also 
correlated negatively with the percentage activated memory cells (r=-0.8457, p<0.0001, Fig. 
3.4 B). Although there was no significant difference in their relative proportions between the 
HIV+ve and HIV-ve groups, there was a positive correlation between the percentages of 
 N Age % Male % Female CD4 count CD19 count 
HIV+ve 21 32 ± 7.84 20% 80% 472.3 ± 237.5 188.6 ± 181.3 
HIV-ve 19 30 ± 8.64 40% 60% 819.9 ± 275.4 276.8 ± 141.8 
p-
value 
- ns - - <0.0001 0.0002 
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transitional cells and plasmablasts in the HIV+ve group (r=0.7219, p=0.0002). These two 
populations were therefore increased in the same HIV+-ve patients, who generally had lower 
CD4 counts. The plasmablast population also correlated positively with percentage activated 
memory cells (r=0.4481, p=0.042). 
The relationship of absolute B-cell count to well-described markers of HIV disease 
progression and immune activation, namely CD3, CD4 and CD8 counts; HIV viral load, and 
CD38 & PD-1 expression on CD8+ T-cells was assessed (Fig 3.3). Absolute B-cell count 
correlated positively with both CD3 and CD8 counts (r=0.2985, p=0,0299, Fig. 3.2 A; 
r=0.2755, p=0.0459, Fig. 3.2 B), but not with CD4 count (r= 0.2277, p= 0.0977, Fig. 3.2 C), 
however a trend towards a positive correlation was noted. As described in other studies, 
CD38 expression on CD8+ T-cells correlated positively with viral load (r=0.5147, p=0.041), 
and negatively with CD4 count (r=-0.4468, p=0.042). CD4 count also correlated negatively 
with PD-1 expression on CD8+ T-cells (r=-0.2440, p=0.0021), therefore healthy individuals 
with higher CD4 counts had lower expression of PD-1 on CD8+ T-cells. The resting memory 
cell population showed a positive correlation with PD-1 on CD8+ T-cells (r=-0.4481, p=0.042, 
Fig. 3.4 F), meaning that resting memory cells were increased in patients with higher levels 
of immune exhaustion. Similarly, percentage resting memory cells correlated positively with 
CD4 count (r=0.4533, p=0.039, Fig. 3.4 D), which indicates that this population was 
decreased in patients with decreased CD4 counts.  
A B C 
Fig. 3.1: Markers of disease progression and immune activation. A) CD4 count was decreased with 
HIV (472.3 ± 237.5 vs. 819.9 ± 275.4; p<0.0001) as expected. B) Absolute B-cell count was also 
decreased with HIV infection (118.6 ± 181.3 vs. 276.8 ± 141.8; p=0.0002). C) The proportion of CD8+T-
cells co-expressing CD38 was increased with HIV infection (46.25 ± 22.94 vs. 28.33 ±17.95; p<0.0001). 
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A B C 
Fig. 3.2. Correlations of Absolute B-cell (CD19), T-cell (CD3), and CD4 counts. A) CD3 count correlated 
positively with absolute B-cell count (r=0.2985, p=0.0299). B) CD8 count also correlated positively with 
absolute B-cell count (r=0.2755, p=0.0459). C) CD4 count did not correlate with absolute B-cell count, 
however a trend towards a positive correlation was noted, and a larger sample size may lead to significance. 
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 HIV+ HIV- p-value 
AMem 12.56 10.53 ns 
PLB 1.45 1.94 ns 
TR 3.50 3.68 ns 
MN 41.83 47.01 ns 
TLMem 24.57 15.43 0.0314 
RMem 17.78 26.33 0.00097 
Fig. 3.3: Ex vivo subset distribution was altered in asymptomatic HIV infection. The 
proportion of resting memory cells ex vivo was significantly decreased with HIV infection 
(p=0.0481), while the proportion of tissue-like memory cells was increased with HIV infection 
(p=0.0314).  
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Fig. 3.4: ex vivo Subset and disease progression marker correlation graphs. A) Relative % 
mature naïve B-cells correlated negatively relative % tissue-like memory B-cells (r=-0.7795, 
p<0.0001). B) Similarly, relative % mature naïve B-cells also correlated negatively with relative % 
activated memory B-cells (r=-0.8457, p=0.001). C) Relative % resting memory B-cells correlated 
negatively with relative % tissue-like memory B-cells (r=-0.4844, p=0.0260). D) There was a 
positive correlation between relative % resting memory B-cells and CD4 count (r=0.2985, 
p=0.0299). E) Relative % activated memory B-cells also correlated positively with relative % 
tissue-like memory B-cells (r=0.6532, p=0.001). F) Similarly, relative % activated memory B-cells 
also correlated positively with the marker of immune exhaustion, PD-1 expression on CD8+ T-cells 
(r=0.4481, p=0.042). 
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3.2 Subset distribution after 18h culture 
 
 After 18h of unstimulated in vitro culture, purified B-cell subset distribution of the HIV+ve 
group, was altered when compared to that observed ex vivo distribution. There was a 
significant change after 18h culture in all subsets except for activated memory cells. There 
was however, no significant difference in subset distribution within the HIV-ve control group 
after 18h unstimulated culture when compared to that of the ex vivo subset distribution in the 
same group (Fig. 3.6). Changes in the HIV+ve group however are not likely to be caused by 
culture stress as there was not alteration in subset distribution with stimulation or inhibition 
relative to that of the unstimulated cells in either group. Alterations were not due to viability 
loss as less than 5% of cells stained positive for Trypan Blue in both the HIV+ve and HIV-ve 
groups after 18h culture with and without stimulation, furthermore, there was no difference in 
cell concentration before and after stimulation (data not shown). Overall population change 
trends following culture were similar for both groups.  
 
Fig. 3.5: Representative data of marker expression on two different subsets in an HIV+ve patient. 
Gating strategy as per chapter 3All plots represent the various peripheral blood subsets, which consist of 
activated memory cells (AMem), resting memory cells (RMem), tissue-like memory cells (TLM), and mature 
naïve (MN) B-cells. A) HIV+ve patient P170 had a relatively-high CD4 count of 437 cells/µl, which correlated 
with higher proportion on RMem cells (r=0.4533, p=0.039, Fig. 3.4 D), meaning that individuals with higher 
CD4 counts had peripheral B-cell subset distributions similar to that of HIV-ve individuals. B) Representative 
subset distribution dotplot of an HIV-ve individual, with the majority of cells in the RMem, and MN 
compartments. C) Representative dotplot of an HIV+ve individual (patient P132 with a CD4 count of 331 
cells/µl), with increased proportions of AMem and TLMem populations. 
B C A 
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Fig. 3.6: Changes in B-cell subset distributions with 18h unstimulated culture. There was 
an increase in the proportions of TLMem (69.31%, p<0.001), and PLB (280%, p<0.001) in the 
HIV+ve group with unstimulated culture. The TR, MN, and RMem populations decreased by 
24.86% (p<0.01), 56.49% and 45.05% respectively (both p<0.001). The proportion of AMem 
was relatively constant between the two conditions. Subset distribution in the HIV-ve group 
was significantly unchanged with 18h unstimulated  
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 ex vivo HIV+ Isolated 
HIV+ 
p-
value 
 ex vivo HIV- Isolated 
HIV- 
p-value 
AMem 12.56 17.26 ns  10.53 13.08 ns 
PLB 1.45 5.51 <0.001  1.94 10.27 ns 
TR 3.50 2.63 <0.01  3.68 0.86 ns 
MN 41.83 18.20 <0.001  47.01 31.74 ns 
TLMem 24.57 41.60 <0.001  15.43 27.16 ns 
RMem 17.78 9.77 <0.001  26.33 18.03 ns 
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3.3 Phenotypic marker expression ex vivo 
3.3.1 The total B-cell population 
3.3.1.1 Expression of activation markers and toll-like receptors 
Overall, there appeared to be a decrease in the percentage of B-cells expressing activation 
markers in the HIV+ve group. For example, the activation marker CD25 was expressed on a 
significantly lower percentage of the total B-cell population in the HIV+ve group (2.42±3.83% 
vs. 4.33±3.38%, p=0.0051, Fig. 3.7 B). There was also a trend towards decreased 
expression of co-stimulatory marker CD86 in the HIV+ group, which approached significance 
(7.69±12.17% vs. 12.50±11.17%, p=0.0545). There was no significant difference in the 
expression of CD126 and CD38 between the two groups (which are both markers of strong 
cellular activation). The expression of VPAC2, the VIP receptor was significantly decreased 
on the HIV+ve total B-cell population, with 1.19±0.77% expression compared to 2.26±2.22% 
in the HIV-ve group (p=0.0296, Fig. 3.7 A). It is possible that this generally minimal increase 
of activation markers ex vivo is due to the fact that the HIV+ve patients in this cohort has 
relatively stable CD4 counts.  
CD284 (Toll-like Receptor 4, an innate LPS receptor) expression on the total B-cell 
population in the HIV+ve group was significantly higher than that of the HIV-ve group 
(40.8±30.50% vs. 24.56±17.51%, p=0.0487). Total CD284 expression also correlated 
positively with Total CD126 expression (r=0.6139, p<0.0001), indicating that IL6 receptor 
expression was significantly increased with increased TLR4 expression, and therefore 
increased exposure to LPS. CD287 expression on the total B-cell population was proposed 
to be indicative of increased viral stimulation (Lanzavecchia & Sallusto, 2007), although its 
expression in the HIV+ve group was not significantly different from that of the HIV-ve group 
(6.40±6.71% vs. 3.34±2.63%, p=0.1101). 
 
3.3.1.2 Inhibitory markers, and a marker associated with apoptosis signaling 
Overall, there was an increase in the percentage of B-cells expressing inhibitory markers, 
with the highest being CD72 (an inhibitory receptor involved in the B-T cell interaction), 
which was significantly higher in the HIV+ve group (60.98±19.50% vs. 38.49±23.68%, 
p=0.0038, Fig. 3.7 C). The percentage of cells expressing CD300a and CD305 (novel 
inhibitory receptors, which bind to phosphatidylserine and collagen respectively), were 
moderately (but not significantly) decreased in the HIV+ group (12.38±6.54% vs. 
17.36±10.73%, p=0.151; & 78.05±13.40% vs. 83.29±7.37%, p=0.244). The percentage of 
cells expressing CD85j, an inhibitory receptor involved in down-regulation of APC activation, 
was moderately, but insignificantly increased in the HIV+ve group, although this was not 
Stellenbosch University  https://scholar.sun.ac.za
 56 
significant (6.82±9.51% vs. 3.92±4.84%, p=0.317). The percentage of cells expressing 
CD300a correlated positively with CD4 count, even though there were no significant 
differences in CD300a expression between the HIV+ve and HIV-ve groups (r=0.4468, 
p=0.042).  
The percentage of B-cells expressing CD307d, a novel marker of cellular exhaustion was not 
significantly different between the HIV+ve and HIV-ve groups, although there was a trend 
towards decreased expression in the HIV+ve group (7.94±8.27% vs. 9.85±7.50%, p=0.2908). 
CD95 expression, which is associated with apoptosis signaling, was not significantly altered 
on the total B-cell population with HIV infection, however total CD95 expression correlated 
positively with total CD307d expression (r=0.6714, p=0.00086). 
 
 
Fig. 3.7: Significantly altered ex vivo activation and inhibitory marker expression on the 
total B-cell population. A) VPAC2 expression was significantly decreased on the HIV+ total B-
cell population, with 1.19±0.77% expression compared to 2.26±2.22% in the HIV- group 
(p=0.0296) B) CD25 expression on the total B-cell population was decreased in the HIV+ group 
(2.42±3.82%) relative to that of the HIV- group (4.33±3.38%), p=0.0051. C) CD72 expression 
on the total B-cell population was increased in the HIV+ group (60.98±19.50%) relative to that 
of the HIV- group (38.49±23.68%), p=0.0038 
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3.3.2 Activated Memory B-Cells 
Activated memory B-cells are the so-called “effector” cells, which have memory against 
previously encountered antigens, and are the active form of resting memory B-cells. 
Previous work has indicated that there is an increase in the relative percentage of these cells 
with HIV infection (Moir & Fauci, 2013), although this study found no significant difference in 
the relative percentages of this subset between the HIV+ve and HIV-ve groups. This may be 
due to the fact that our small cohort had relatively high CD4 counts, and were clinically 
asymptomatic.  
3.3.2.1 Expression of activation markers and toll-like receptors 
The relative percentage of activated memory B-cells expressing CD86 was minimally (but 
significantly) decreased, similar to as observed in the total B-cell population, however this 
was a minor shift (7.09±6.24% vs. 9.46±5.23%, p=0.048, Fig. 3.8 B). The percentage 
activated memory B-cells expressing CD38, a marker of early cell activation, was 
significantly increased within the HIV+ group by a large margin (38.63±11.82% vs. 
24.21±8.96%, p=0.0004, Fig. 3.8 A), even though there was no significant alteration in the 
total B-cell population. CD284 expression, although expressed on almost twice as many 
cells in the total population (p=0.0487), was not significantly altered on activated memory B-
cells by HIV infection. CD287 expression on activated memory cells was consistent with that 
of the total B-cell population, in that expression was also not significantly altered by HIV 
infection. 
3.3.2.2 Inhibitory markers, and a markers associated with apoptosis signaling 
Consistent with the findings in the total B-cell population, CD72 expression on activated 
memory cells was significantly increased in the HIV+ve group (33.33±20.08%, vs. 
20.74±17.66% in the HIV-ve group, p=0.0396, Fig. 3.9 A). Conversely, while there was no 
significant difference in either CD300a, or CD305 expression on the total B-cell population, 
expression of both on activated memory cells in the HIV+ve group was decreased relative to 
that of the HIV-ve group (19.67±10.17% vs. 29.89±13.64%, p=0.0213, Fig. 3.9 B for CD300a; 
and 60.91±17.88% vs. 70.74±11.26%, p=0.048, Fig. 3.9 D for CD305). Unlike that of the 
total B-cell population, CD307d expression on activated memory cells ex vivo was 
significantly increased in the HIV+ve group, with a mean of 25.75±10.04% compared to 
15.27±15.27% in the HIV- group (p=0.0015, Fig. 3.9 C). There was no significant change ex 
vivo in CD95 expression on activated memory cells with HIV infection, which is consistent 
with the expression found on the total B-cell population. 
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Fig. 3.8: Significantly altered ex vivo activation marker expression on activated 
memory cells. A) CD38 expression was increased on HIV+ activated memory cells, 
with a mean of 38.63±11.82% compared to 22.40±8.96% in the HIV- group 
(p=0.0004). B) CD86 expression on activated memory cells was decreased in the 
HIV+ group, with a mean of 7.09±6.24% compared to 9.46±5.23% in the HIV- group 
(p=0.048). 
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In summary, the activated memory B-cell subset in the HIV+ve group exhibited an increase in 
CD38 expression (approximately 38%), which was concomitant with a decrease in CD86 
expression (approximately 20%), both of which were not significantly altered in the total B-
cell population. Of the inhibitory markers used in this study, only CD72 was significantly 
expressed at higher levels on activated memory B-cells (approximately 38% higher than that 
of the HIV-ve group), while the marker of exhaustion, CD307d was also increased on this 
subset with HIV infection. CD300a and CD305 expression was decreased, and CD95 
expression on this subset were not significantly altered by HIV infection. 
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Fig. 3.9: Ex vivo inhibitory and exhaustion marker expression on activated memory cells. A) 
CD72 expression on activated memory cells was increased in the HIV+ group, with a mean of 
33.33±20.08% compared to 20.74±17.66% in the HIV- group (p=0.0396). B) CD300a expression was 
decreased on HIV+ activated memory cells, with a mean of 19.67±10.17% compared to 
29.89±13.64% in the HIV- group (p=0.0213). C) CD307d expression on activated memory cells was 
increased in the HIV+ group, with a mean of 25.75±10.04% compared to 15.27±15.27% in the HIV- 
group (p=0.0015). D) CD305 expression on activated memory cells was decreased in the HIV+ group, 
with a mean of 60.91±17.88% compared to 70.74±11.26% in the HIV- group (p=0.0480) 
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3.3.3 Resting Memory B-cells 
Resting memory B-cells are the quiescent population within the memory compartment. 
When they encounter cognate antigen, they are re-activated and proceed to proliferate into 
effector (activated) memory B-cells. This compartment has been found to be decreased with 
HIV infection (Moir & Fauci, 2013), which has been confirmed in this study. 
3.3.3.1 Expression of activation markers and toll-like receptors  
CD126 expression (the IL-6 receptor) was significantly increased by roughly 60% in the 
HIV+ve resting memory subset (39.01±25.59% vs. 14.89±9.48%, p=0.0008; Fig. 3.10 A), 
while its expression was not significant on either activated memory B-cells, or the total B-cell 
population. Relative expression of CD25 (the Il-2 receptor) was significantly decreased on 
resting memory cells (1.76±2.11% vs. 3.91±3.26%, p=0.0017, Fig. 3.10 B) with HIV 
infection, although these values were both at relatively low levels (<5% expression). 
Interestingly, there was no significant difference in CD25 expression on activated memory 
cells, however its expression was consistent with the expression pattern of CD25 on the total 
B-cell population (<5%).  
Relative CD284 expression, while not significantly altered on either activated memory B-
cells, or the total population by HIV infection, was expressed on approximately 50% more 
resting memory cells in the HIV+ve group, with a mean of 51.43±30.12%, compared to 
24.84±10.07% in the HIV-ve group (p=0.0057, Fig. 3.10 D). CD287 was also expressed on a 
significantly larger proportion of resting memory B-cells in the HIV+ve group, with a mean of 
10.60±13.10%, compared to 3.44±2.61% in the HIV-ve group (p=0.0199, Fig. 3.10 C). This 
was in contrast to the total B-cell population, and activated memory B-cell subset, on which 
there was no significant difference in CD287 expression. 
3.3.3.2 Inhibitory markers, and a marker associated with apoptosis signaling 
There was no significant difference in CD307d expression between the two groups, although 
there was a trend towards increased expression in the HIV+ve group (10.96±6.47% vs. 
8.18±2.96%, p=0.1672). There was no significant change ex vivo in CD72, CD85j, CD300a, 
CD305, or CD95 expression on resting memory cells with HIV infection. 
In summary, the resting memory B-cell subset had increased expression of CD126 
(approximately 60%), CD284 (approximately 50%), and CD287 (approximately 68%), while 
CD25 expression was decreased (although the expression of this marker on the HIV-ve group 
was <5%). None of the inhibitory markers in this study were significantly altered on resting 
memory B-cells ex vivo by HIV infection. 
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Fig. 3.10: Ex vivo activation marker and TLR expression on resting memory cells. A) 
CD126 expression on resting memory cells was increased in the HIV+ group, with a mean 
of 39.01±25.99% compared to 14.89±9.48% in the HIV- group (p=0.0008). B) CD25 
expression was decreased on HIV+ resting memory cells, with a mean of 1.76±2.11% 
compared to 3.91±3.26% in the HIV- group (p=0.0017). C) CD287 expression on resting 
memory cells was increased in the HIV+ group, with a mean of 10.60±13.10% compared to 
3.44±2.61% in the HIV- group (p=0.0199). D) CD284 expression on resting memory cells 
was increased in the HIV+ group, with a mean of 51.43±30.12% compared to 
28.84±10.07% in the HIV- group (p=0.0057). 
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3.3.4 Tissue-like Memory B-cells  
Tissue-like memory B-cells are the so-called “exhausted” B-cell subset, which constitutes the 
largest peripheral blood B-cell subset in HIV infection. These cells are derived from the 
memory B-cell compartment, which after activation, eventually become anergic and gain 
increased surface expression of inhibitory receptors, while losing activation marker 
expression (Moir & Fauci, 2013). In the current study this subset was found to be 
significantly increased (see above). 
3.3.4.1 Expression of activation markers and toll-like receptors 
As expected due to their loss of function (linked to loss of activation marker expression), 
there was no significant difference in activation marker expression on the tissue-like memory 
B-cell subset between the two groups, except for CD287 (TLR 7, Fig. 3.11), indicative of 
increased levels of viral stimulation in vivo. CD287 was expressed on significantly more 
tissue-like memory cells in the HIV+ve group, with a mean of 8.28±11.39%, compared to 
1.12±1.32% in the HIV-ve group (p=0.0128). This level of expression was consistent with that 
of the activated- and resting memory B-cell subsets (approximately 10%), and slightly higher 
than that of the total B-cell population (approximately 6%).  
 
Fig. 3.11: Ex vivo TLR7 expression on tissue-like memory B-cells was increased in 
the HIV+ group (8.28±11.39%) relative to that of the HIV- group (1.12±1,32%), p=0.0128 
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3.3.4.2 Inhibitory markers and Fas (CD95), a marker associated with apoptosis 
signaling  
The marker that exhibited the most dramatic increase on tissue-like memory B-cells with HIV 
infection was CD72, which was increased 1.45-fold compared to the HIV-ve group 
(70.88±16.54% vs. 28.83±25.68%, p<0.0001; Fig. 3.12 A). This significant increase in CD72 
expression on this subset is greater than that of the total B-cell population and activated 
memory B-cell population (both approximately 38%, Fig. 3.7 A and Fig. 3.9 A respectively). 
Relative CD85j expression when compared to the HIV-ve group was 1.7-fold higher 
(19.38±23.18% vs. 7.09±10.39%, p=0.046, Fig. 3.12 B), and this was also the only subset in 
which there was a significant difference in CD85j expression with HIV infection, ex vivo.  
CD307d expression, which is a hallmark of this subset, was significantly raised in the HIV+ve 
group, with a mean of 12.93±10.32%, compared to 7.5±5.10% in the HIV-ve group (p=0.045, 
Fig. 3.12 C). This was however; lower than that of the activated memory B-cell subset, 
where expression was increased by 40% to 25.75±10.04%. CD307d expression on both 
resting memory B-cells, and the total B-cell population was <10%, and not significantly 
altered with HIV infection. There was no significant change ex vivo in CD95 expression on 
tissue-like memory cells with HIV infection. 
In summary, none of the activation markers used in this study were found to have 
significantly altered expression on the HIV+ve group, except for CD287, which has similar 
expression levels compared to the activated- and resting memory B-cell subsets, and was 
slightly higher than that of the total B-cell population. The tissue-like memory B-cell subset 
had extremely high expression of CD72, while its expression of CD307d was lower than that 
of the activated memory B-cell subset. Significant expression of CD85j was noted on this 
subset, and on no others, while CD300a, CD305, and CD95 had expression not significantly 
altered by HIV infection.  
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Fig. 3.12: Ex vivo Inhibitory marker expression. A) CD72 expression was increased on tissue-like 
memory B-cells in the HIV+ group (70.88±16.54%) compared to the HIV- control (28.83±25.68%; 
p<0.0001). B) CD85j expression on tissue-like memory B-cells in the HIV+ group was increased 
compared to the HIV- control group (19.38±23.18% vs. 7.09±10.39%; p=0.046). C) CD307d 
expression on tissue-like memory B-cells was increased in the HIV+ group relative to that of the 
HIV- controls (12.93±10.32% vs. 7.50±5.10%; p=0.045) 
C A B CD72+ Tissue-like Memory Cells
P - TLM CD72 N - TLM CD72
0
20
40
60
80
100
p<0.0001
HIV+ HIV-
%
 E
xp
re
ss
io
n
CD85j+ Tissue-like Memory Cells
P - TLM CD85j N - TLM CD85j
0
20
40
60
80
p=0.0463
HIV+ HIV-
%
 E
xp
re
ss
io
n
CD307d+ Tissue-like Memory cells
P - TLM CD307d N - TLM CD307d
0
20
40
60
p=0.0450
HIV+ HIV-
%
 E
xp
re
ss
io
n
 
3.3.5 Mature Naïve B-cells 
Mature naïve B-cells constitute the highest percentage of peripheral blood B-cells in healthy 
individuals, and are the mature form of the naïve B-cell as it exits the bone marrow. These 
cells are antigen naïve, and as such should express low levels of both activation, and 
inhibitory markers ex vivo (Moir & Fauci, 2013). 
3.3.5.1 Expression of activation markers and toll-like receptors 
Relative expression of CD126 on mature naïve B-cells was increased by 260% 
(21.56±32.25% vs. 5.91±7.83%, p=0.023; Fig. 3.13 A), which was higher than the 60% 
increase found on resting memory B-cells (although overall expression was higher, at 
39.01±25.59%). CD126 expression was not significantly altered on the total B-cell 
population, or the activated- , or tissue-like memory subsets. Expression of the other 
markers of activation (CD70, CD38, and CD25), as well as the toll-like receptors (CD287 and 
CD284), used in this study were not significantly altered on the HIV+ve group, compared to 
the HIV-ve group.  
3.3.5.2 Inhibitory markers, and Fas (CD95) 
CD72 had the highest level of expression on this subset (77.49±23.45% vs. 45.32±36.02% 
in the HIV-ve group, p=0.0026, Fig. 3.13 C), although there was only a difference of ~40% 
between the relative expressions of the two groups (compared to an approximate difference 
of 60% and 38% on tissue-like memory B-cells, and resting- and activated memory B-cells 
respectively). Mature naïve B-cells in the HIV+ve group also had increased CD307d 
expression ex vivo, with a mean of 7.49±10.05%, compared to 2.58±2.27% in the HIV-ve 
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group (p=0.0135, Fig. 3.13 B), although this was lower than that of the activated memory 
subset. Lastly, there was no significant change ex vivo in CD95 expression on mature naïve 
B-cells with HIV infection, which was consistent with the other subsets, as well as with the 
overall relative CD95 expression on the total B-cell population. 
In summary, this subset expressed CD126 at levels close to that of the resting memory 
subset, while the other markers of activation used in this study were not significantly 
changed by HIV infection. Of the markers of inhibition used in this study, CD72 was 
consistently expressed significantly on all subsets except for resting memory B-cells, and the 
mature naïve B-cell subset had the highest expression of all (77.49±23.45%), although the 
percentage difference between the HIV+ve and HIV-ve groups was the second highest at 
41.51% (compared to 59.33% with tissue-like memory B-cells). CD307d was expressed a 
low levels on this subset (<10%), although this was significantly higher than that of the HIV-ve 
group (<5%).  
Fig 3.14: Ex vivo activation (CD126) and inhibitory (CD72 and CD307d) marker expression 
on mature naïve B-cells. A) CD126 expression was increased on mature naïve B-cells in the 
HIV+ group (21.56±32.25%) compared to the HIV- control (5.91±7.83%; p=0.023). B) CD307d 
expression on mature naïve B-cells in the HIV+ group was increased compared to the HIV- 
control group (7.49±10.05% vs. 2.58±2.27%; p=0.0135). C) CD72 expression on tissue-like 
memory B-cells was increased in the HIV+ group relative to that of the HIV- controls 
(77.49±23.45% vs. 45.32±36.02%; p=0.0026) 
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3.4 Effect of TLR Stimulation on the Total B-cell Population and 
Individual Subsets, and the Subsequent Impact of VIP Inhibition  
This section details the results of the TLR stimulation (with either LPS, or R848), and the 
impact of VIP on stimulation-induced changes. These experiments were performed in order 
to assess whether B-cells from HIV+ve and HIV-ve individuals responded differently to either 
of the two innate stimuli as measured by expression of the above-mentioned markers of 
activation, inhibition, exhaustion, and apoptosis signaling. VIP was examined as a putative 
inhibitor of stimulation events in order to assess its potential as a selective inhibitor of 
cellular activation. Interestingly, even though CD284 (LPS TLR) expression was relatively 
high on resting memory cells ex vivo compared to CD287 (R848 TLR) on the same subset 
(Fig. 3.10 D), on the whole R848 elicited a far greater response than LPS. As a result the 
majority of the data described are based on R848 stimulation.  
Marker expression and subset distribution ex vivo was compared to that of the isolated cells, 
both immediately after isolation (data not shown), and after 18h unstimulated culture 
(Appendix A, Table 1). B-cells from HIV-ve individuals as a whole were not significantly 
altered by either isolation, or unstimulated culture, where marker expression throughout 
remained essentially unchanged when compared to ex vivo expression. B-cells from HIV+ve 
individuals also did not have significantly altered expression post-isolation, but had some 
significant alterations after 18h unstimulated culture. This important finding gives an early 
indication that B-cells from HIV+ve individuals are extremely sensitive to stimulation and may 
be pre-primed in vivo. [See Appendix A for full list of tables showing the differences in 
marker expression between the HIV+ve and HIV-ve groups for each subset in response to 
TLR stimulation and VIP inhibition. 
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Table 3.2. Summary results of response activation, inhibition, exhaustion, and 
apoptosis signaling markers to R848 stimulation, and to VIP inhibition. Data is 
represented as a significant increase (é) or decrease (ê), or non-significant change (¢). 
The number of arrows indicates the significance level, where one arrow - p<0.05; two arrows 
- p<0.01; and three arrows - p<0.001.  
 Total B Amem Rmem TLMem MN 
 R848 VIP R848 VIP R848 VIP R848 VIP R848 VIP 
Activation           
CD25 é ¢ ¢ ¢ ¢ ¢ éé ¢ éé êê 
CD38 é ê ¢ ¢ ¢ ¢ ¢ ¢ ¢ êê 
CD86 éé êê éé êê ééé ê éé ê é êê 
CD126 ¢ ¢ ¢ ¢ é ¢ ¢ ¢ ¢ ¢ 
TLR           
CD284 ¢ ê ¢ ê ¢ ¢ ¢ ¢ ¢ ê 
CD287 é ê é ¢ ¢ ¢ ¢ ê é ¢ 
Inhibition           
CD72 é êê ¢ êê ¢ ¢ é êê ¢ ¢ 
CD85j ¢ ê ¢ ¢ ¢ ¢ ¢ ¢ ééé êê 
CD300a ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ 
CD305 ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ 
CD307d ¢ ê éé ¢ ééé ¢ éé ¢ ééé ê 
Apoptosis 
Signaling 
          
CD95 ééé ê é ê ééé ¢ éé êê éé ê 
 
 
3.4.1 Total B-cell Population 
3.4.1.1 Activation marker, VPAC2, and toll-like receptor expression  
Total B-cell CD38 expression increased by 7.02% from 45.43±13.37% at baseline to 
48.62±21.78% with R848 stimulation (p<0.05; Fig. 3.14 A), and interestingly, presence of 
VIP resulted in a further 21.76% decrease in total B-cell CD38 expression to that of 
59.20±10.15% (p<0.05), which is also significantly higher than that of the baseline (p<0.05). 
CD38 expression was also not significantly altered by HIV infection on the total B-cell 
population ex vivo. 
Total B-cell CD86 expression increased from 34.99±28.83% in the unstimulated control to 
46.11±32.88% (p<0.01; Fig. 3.14 B) with R848 stimulation. Addition of VIP resulted in a 
38.3% decrease (p<0.05) in CD86 expression to 28.45±19.37%, which was also significantly 
below that of the baseline (p<0.01). This is in stark contrast to the response of CD38 to VIP, 
which resulted in an increased expression. Increased CD38 expression is linked to 
increased movement of intracellular Ca2+, while CD86 expression is involved in T-cell co-
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stimulation, thereby indicating that even though both are markers of activation; they have 
independent downstream events to TLR stimulation. 
Total B-cell CD25 expression was low ex vivo (<5%), but was significantly up-regulated with 
R848 stimulation, compared to the unstimulated control (9.65±8.57% vs. 22.17±22.69%, 
p<0.05), and although there was slight down-regulation in the presence of VIP, the results 
were not statistically significant. Activation marker expression of the HIV-ve total B-cell 
population was not significantly changed by either TLR stimulation, or VIP inhibition. 
Neither LPS, nor R848 stimulation significantly altered CD126, or CD70 expression on the 
total B-cell population within the HIV+ group. CD70 expression remained non-significantly 
altered in all subsets in all conditions. 
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Fig. 3.14: Total B-cell activation marker (CD38 and CD86), and TLR 7 expression after 
R848 stimulation, and the impact of VIP A) Total B-cell CD38 expression was raised 
upon R848 stimulation (p<0.05), further up-regulated with VIP inhibition (p<0.05). B) Total 
B-cell expression of CD86 was increased upon R848 stimulation (p<0.01), and significantly 
decreased upon VIP inhibition (p<0.05). C) Total B-cell expression of CD287 was 
increased upon R848 stimulation (p<0.05), and significantly decreased upon VIP inhibition 
(p<0.05). 
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CD287 expression on the total B-cell population was raised significantly from 21.35±25.79% 
at baseline, to 23.43±31.43% with R848 stimulation (p<0.05), while there was no significant 
change with LPS stimulation. VIP was an effective inhibitor of CD287 expression on the total 
population, where inhibition induced a down-regulation of CD287 expression by 59.23% (to 
a mean of 8.06±11.59%; p<0.05, Fig. 3.14 C). 
There was no significant change in CD284 expression on the total B-cell population with TLR 
stimulation. However, similar to CD287 expression, VIP was also an effective inhibitor of 
enhanced CD284 expression by R848. Expression decreased from 71.56±33.52% to 
48.45±33.24% (p<0.05)  
VPAC2 expression was only measured on the total B-cell population, due to limitations in 
fluorochrome-conjugated antibody availability. There was no significant change in VPAC2 
expression with TLR stimulation, and also no significant VIP inhibition of VPAC2 expression. 
There was also no significant difference in VPAC2 expression on the total B-cell population 
between the HIV+ and HIV- groups in any of the stimulation or inhibition conditions.  
 
 
 
Fig. 3.15. Representative flow cytometry dotplots showing total CD86 expression at baseline, 
with R848 stimulation, and upon VIP inhibition. A) Total CD86 expression on HIV+ve patient P168 
at unstimulated (US) baseline (6.26%, quadrant G++). B) Total CD86 expression on the same patient 
was 26.48% with R848 stimulation (G++). C). CD86 expression on the same patient after VIP 
inhibition was 15.17% (G++). 
C A B 
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3.4.1.2 Inhibitory receptors (CD72, CD85j, CD305, CD300a, CD307d), and a marker 
associated with apoptosis (CD95) 
 
Total B-cell expression of CD72 was raised in the HIV+ve group ex vivo, interestingly, it was 
significantly down-regulated by ~ 17% with TLR (only LPS) stimulation (from 21.81±15.07% 
to 18.10±14.33%, p<0.05), and underwent a further 59.03% decrease in presence of VIP 
inhibition to 7.41±6.57% (p<0.01). VIP thus successfully inhibited CD72 expression on the 
total B-cell population, to levels below 10% (8.23±6.77%), which was also significantly lower 
than that of the baseline (p<0.01, Fig. 3.16 D).  
Neither CD300a, nor CD305 expression on the total B-cell population were significantly 
altered by HIV infection ex vivo, nor was there a response to TLR stimulation or VIP 
inhibition. TLR stimulation was also unable to elicit any significant changes in CD85j 
expression on the total B-cell population, although it was significantly downregulated with 
VIP inhibition (p<0.05, Fig. 3.16 A).  
Ex vivo expression of CD307d on the total B-cell population was not significantly altered by 
HIV infection, nor was it significantly altered by TLR stimulation or VIP inhibition (Fig. 3.16 
C). While there were no significant differences ex vivo, potential sensitivity to 
apoptosis/apoptosis signaling, as measured by CD95 expression, was increased by 19.35% 
to 51.37±35.91% with R848 stimulation (p<0.001). Furthermore, apoptosis signaling 
decreased by 63.27%, to 18.87±8.19% after VIP inhibition (p<0.05). This was also 
significantly lower than the baseline of 43.04±31.45% (p<0.05). B-cell apoptosis signaling in 
the HIV-ve group was also not responsive to either TLR stimulation, or VIP inhibition, 
although the levels of CD95 expression were consistently <14% (lower than the VIP-
inhibited HIV+ve group, p<0.05, Fig. 3.16 B). The fact that CD95 was only upregulated in 
HIV+ve individuals (and not HIV-ve controls) indicates that innate stimulation may play a very 
important role in driving Fas-mediated apoptosis signaling (in a manner similar to that found 
in CD4+ T-cells).  
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Expression of both activation, and inhibitory markers on the total B-cell population in general 
showed the best stimulation-induced response to R848, with the exception of CD72, which 
responded to LPS, and not R848. CD70 expression on the total B-cell population was 
increased with R848 stimulation; however these levels were below 5%. CD38, CD86, and 
CD25 displayed significantly increased expression after R848 simulation, however VIP 
inhibition was only able to significantly down-regulate CD86 expression. CD287, and not 
CD284 expression was significantly up-regulated by R848 stimulation where approximately 
25% of cells expressed CD287. VIP, however successfully inhibited expression of both 
CD287, and CD284 to levels below 10% and 50% respectively. 
CD72 was the only marker of inhibition that was significantly altered by TLR stimulation, by 
which it was decreased, while VIP inhibition further decreased CD72 expression to levels 
well below the baseline. Of particular interest is the response of the apoptosis-signaling 
marker, CD95, which displayed a significant response to TLR stimulation in comparison to 
that of the HIV-ve group; and also its response to VIP inhibition, which resulted in expression 
only approximately 20% greater than the HIV-ve group.  
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Fig. 3.16: Significantly altered expression of markers of inhibition (CD85j, 
CD72), exhaustion (CD307d) and apoptosis signaling (CD95) on the total HIV+ve 
B-cell population after TLR stimulation and VIP inhibition. A) Total B-cell CD85j 
expression on the total B-cell population was not significantly altered by R848 
stimulation, however VIP inhibition resulted in a significant down-regulation in CD85j 
expression relative to the stimulated cells (p<0.05). B CD95 expression on the total B-
cell population was significantly raised upon R848 stimulation (p<0.001), while VIP 
inhibition resulted in a near complete down-regulation of CD95 expression (p<0.05). 
C) Total B-cell CD307d expression was not significantly altered by R848 stimulation, 
however VIP inhibition resulted in a significant down-regulation in expression relative 
to the stimulated conditions (p<0.05). D) Total B-cell CD72 expression was raised 
upon R848 stimulation (p<0.05), and further decreased upon VIP inhibition (p<0.01). 
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3.4.2 Activated Memory B-cells 
Activated memory B-cells in the HIV+ve group expressed increased levels of CD38, and 
decreased levels of CD86 compared to the HIV-ve group ex vivo. There was no significant 
change in other markers of activation with this subset. CD72 and CD307d expression was 
increased relative to that of the HIV-ve group, while CD300a and CD305 had decreased 
expression, and CD95 expression was not significantly altered by HIV infection. See below 
for summary table of results for AMem B-cells response to R848 stimulation, and VIP 
inhibition.  
Table 3.3 Summary results of marker percentage change with R848 stimulation and 
VIP inhibition, relative to baseline unstimulated conditions on activated memory B-
cells. Negative percentage indicates percentage decrease; * = p<0.05, ** = p<0.01, ns = not 
significant. Significant data further indicated in bold. 
3.4.3 Resting Memory B-cells 
Resting memory B-cells had an interesting expression pattern ex vivo, where there was 
significant up-regulation of activation markers with HIV infection, while inhibitory and 
apoptosis signaling markers were not significantly altered with HIV infection. CD126 was 
significantly increased by 60%, while CD284 was increased by roughly 25% on resting 
memory B-cells in the HIV+ve group ex vivo (p=0.0145, and p=0.0057), respectively. CD287 
expression was increased to levels above 10% with HIV infection (compared to <5%, 
p=0.0199). CD25 expression was decreased with HIV infection, however these levels were 
very low (both <5%, p=0.0017). See below for summary table of results for RMem B-cells 
response to R848 stimulation, and VIP inhibition. 
 R848-induced % change VIP-induced Inhibition 
Activation  p value  p value 
CD25 120,7% ns -81,2% ns 
CD38 13,57% ns -1,0% ns 
CD86 42,2% ** -46,4% ** 
CD126 1,3% ns -15,5% ns 
TLR      
CD284 3,1% ns -28,6% * 
CD287 18,5% * -62,8% ns 
Inhibition     
CD72 5,2% ns -70,2% ** 
CD85j 22,9% ns -44,9% ns 
CD300a 9,4% ns -29,6% ns 
CD305 -8,4% ns -17,0% ns 
CD307d 25,3% ** -36,6% ns 
Apoptosis Signalling     
CD95 21,7% * -74,86% * 
Stellenbosch University  https://scholar.sun.ac.za
 74 
Table 3.4 Summary results of marker percentage change with R848 stimulation and 
VIP inhibition, relative to baseline unstimulated conditions on resting memory B-cells. 
Negative percentage indicates percentage decrease; * = p<0.05, ** = p<0.01, *** = p>0.001, 
ns = not significant. Significant data further indicated in bold. 
 
3.4.4 Tissue-like Memory B-cells 
The overall phenotypic profile of this subset ex vivo showed a tendency towards being 
inhibitory in nature, with up-regulated expression of both CD72 (1.46-fold, p<0.0001), and 
CD85j (1.73-fold, p=0.046). Tissue-like memory B-cells also had increased evidence of viral 
stimulation, due to an increase in TLR7 (CD287) expression (6.42-fold, p=0.0128), as well 
as a tendency towards being functionally exhausted due to up-regulated CD307d expression 
(72.33% increase relative to the HIV-ve group, p=0.045). 
3.4.4.1 Expression of activation markers (CD25, CD38, CD70, CD86, & CD126), and toll-
like receptor (CD284 & CD287.) expression 
 
CD86 expression on tissue-like memory cells in the HIV+ group increased from 
27.39±23.16% to 34.84±25.56% with R848 stimulation (p<0.01), and decreased by 44.49% 
with VIP inhibition to 19.34±7.97% (p<0.05). CD86 expression after VIP inhibition was also 
significantly lower than that of baseline (p<0.01; Fig. 3.17 B). This expression pattern is in 
concert with that of the total B-cell population where there was an increase in expression 
with R848 stimulation, and a further decrease with VIP inhibition.  
CD25 expression was increased on tissue-like memory cells with TLR stimulation in the 
HIV+ group (5.33±6.00% vs. 16.25±17.92%, p<0.01), and VIP down-regulated expression 
 R848-induced % change VIP-induced Inhibition 
Activation  p value  p value 
CD25 159,6% ns -83,7% ns 
CD38 8,8% ns 11,1% ns 
CD86 56,1% ** -55,3% * 
CD126 9,6% * -27,2% ns 
TLR     
CD284 -7,9% ns -19,9% ns 
CD287 19,3% ns -74,8% ns 
Inhibition     
CD72 -0,7% ns -62,3% ns 
CD85j 41,3% ns -61,4% ns 
CD300a 5,3% ns -19,0% ns 
CD305 2,5% ns -11,0% ns 
CD307d 41,7% *** -14,7% ns 
Apoptosis Signalling     
CD95 31,1% *** -64,0% ns 
Stellenbosch University  https://scholar.sun.ac.za
 75 
(p<0.01) to levels similar to that of the baseline (1.98±1.63; Fig. 3.17 A). This is consistent 
with the pattern of CD25 expression on both the resting memory subset, as well as the total 
B-cell population, where although VIP inhibition did not decrease expression significantly, 
there was a definite trend noted.  
Interestingly, CD287 expression on tissue-like memory cells was not significantly changed 
by TLR stimulation, however there was a significant down-regulation in its expression with 
VIP inhibition, from 9.69±14.32% (R848-stimulated) to essentially complete abrogation of 
expression (1.08±1.18%; p<0.05).  
 
CD126, CD38, and CD284 expression on tissue-like memory cells was slightly raised with 
R848 stimulation, and lowered with VIP inhibition, but these were not statistically significant. 
CD70 was not expressed on tissue-like memory cells, and no subsequent alterations were 
noted with TLR stimulation or VIP inhibition 
 
3.4.4.2 Inhibitory markers (CD72, CD85j, CD300a, CD305, & CD307d.) and CD95 
CD72 expression on tissue-like memory cells was significantly altered by R848 stimulation in 
the HIV+ group, where expression was raised by 51.55% from 9.54±9.35% at baseline, to 
14.45±14.12% with R848 stimulation (p<0.05; Fig. 3.18 A). VIP inhibition resulted in a 
decrease in CD72 expression to 2.16±2.30% (p<0.01), which was also significantly lower 
Fig. 3.17: Activation marker (CD25 and CD86) expression on tissue-like memory B-
cells. A) CD25 expression on TLMem B-cells was raised significantly by R848 stimulation 
(p<0.01), while VIP inhibition resulted in expression not significantly different to that of the 
un-stimulated baseline. B) CD86 expression was significantly raised on TLMem B-cells 
upon R848 stimulation (p<0.01), and subsequently decreased with VIP inhibition, to levels 
significantly lower than that of the un-stimulated baseline (p<0.01). 
ns ** 
ns * ** 
** 
CD25 on TLMem
0
20
40
60
80
Unstim R848 R848+VIP
CD86 on TLMem
0
20
40
60
80
100
Unstim R848 R848+VIP
Stellenbosch University  https://scholar.sun.ac.za
 76 
than baseline of 9.54±9.35% (p<0.01). CD72 was not expressed on tissue-like memory B-
cells in the HIV-ve group  
In a manner consistent with the other subsets, CD95 expression on tissue-like memory cells 
was significantly raised with TLR stimulation, from 38.68±32.55% at baseline, to 
46.98±37.26% (p<0.01, Fig. 3.18 B). Inhibition with VIP resulted in a mean CD95 expression 
that was 66.47% below baseline, and 72.39% below that of the TLR-stimulated cells (both 
p<0.01). CD95 expression on this subset in the HIV-ve group was unaffected by both TLR 
stimulation, and VIP inhibition (Appendix A, Table 10).  
CD307d expression is one of the hallmark features of this subset, and while minimal 
expression was noted ex vivo (12.93±10.32%), there was no significant change with 
overnight culture (11.30±6.96, Fig. 3.18 C). Furthermore, this subset had the second-lowest 
expression of CD307d at baseline (mature naïve B-cells had the lowest expression at 
baseline). There was an increase in CD307d expression upon TLR stimulation (to 
14.96±8.85; p<0.01), however, there was no significant alteration after VIP inhibition. 
CD300a, Cd305, and CD85j expression in the HIV+ve group remained unchanged with both 
TLR stimulation and VIP inhibition and VIP inhibition. 
C A B 
Fig. 3.18: Inhibitory (CD72), exhaustive (CD307d), and apoptosis-signaling (CD95) marker 
expression on tissue-like memory B-cells after R848 stimulation, and VIP inhibition. A) CD72 
expression was up-regulated upon R848 stimulation (p=0.05), and further down-regulated upon VIP 
inhibition to levels below that of the un-stimulated baseline (p<0.01). B) CD95 expression on TLMem 
B-cells was significantly raised by R848 stimulation (p<0.01), and further decreased to levels 
significantly lower than the un-stimulated baseline (p<0.01). C) CD307d expression was up-regulated 
upon R848 stimulation (p<0.01), while VIP inhibition resulted in expression that was not significantly 
different from that of the un-stimulated baseline. 
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3.4.5 Mature Naïve B-cells 
Mature naïve B-cells had an ex vivo profile that was surprisingly varied, where markers of 
activation, inhibition, and exhaustion were up-regulated with HIV infection. CD126, the IL-6 
receptor was up-regulated 2.65-fold in the HIV+ve group (p=0.0237), while CD72 was up-
regulated by 70.98% with HIV infection (p=0.0026), and CD307d up-regulated 1.90-fold 
(p=0.0135). These cells are cognate antigen naïve, and as such should express low levels of 
both activation, and inhibitory markers ex vivo, which indicates that there is possibly due to 
increased innate antigenic stimulation with HIV infection. 
 
3.4.5.1 Expression of activation markers (CD25, CD38, CD70, CD86, & CD126), and toll-
like receptor (CD284 & CD287.) expression 
CD86, a marker of T- cell co-stimulation, and therefore activation, had the lowest expression 
of all subsets on mature naïve B-cells, although there was a response to TLR stimulation, 
where expression increased from 13.57±14.83% at baseline, to 22.59±21.88% (p<0.05; Fig. 
3.19 A). Subsequent VIP inhibition resulted in expression of 8.82±9.78%, which is 
significantly lower than both the TLR stimulated-, and baseline conditions (both p<0.01).  
Interestingly, CD38 expression had the highest expression of all subsets, on mature naïve B-
cells. While there was no significant change with TLR stimulation, VIP inhibition resulted in a 
significant decrease (albeit minor) in expression compared to both the TLR-stimulated 
(61.73±22.19% vs. 60.94±21.49%, p<0.01), and baseline conditions (63.46±22.17% vs. 
60.94±21.49%, p<0.05; Fig. 3.19 B). 
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Fig. 3.19: Activation marker (CD86, CD38, CD25) expression on mature naïve B-cells after R848 
stimulation, and VIP inhibition. A) CD86 expression was raised with R848 stimulation (p<0.05), and 
subsequently decreased to levels below that of the un-stimulated baseline with VIP inhibition (p<0.01). 
B) CD38 expression on MN B-cells was not significantly raised by R848 stimulation, and decreased to 
levels significantly different from the un-stimulated baseline (p<0.01). C) CD25 expression was 
increased 14-fold R848 stimulation (p<0.01), while VIP inhibition resulted in a CD25 expression that was 
not significantly different to that of the un-stimulated baseline.  
** * 
** ** ns 
** 
** 
ns 
CD86 on MN
0
20
40
60
Unstim R848 R848+VIP
** 
Stellenbosch University  https://scholar.sun.ac.za
 78 
CD25 was essentially not expressed at baseline, and responded significantly to TLR 
stimulation with an increase from 1.81±2.11% to 14.27±19.09% (p<0.01; Fig. 3.19 C). 
Similarly, mean expression decreased to 0.27±0.24% with VIP (p<0.01). This trend in CD25 
expression was noted throughout all subsets except for activated memory B-cells, where 
there was no statistically significant change in CD25 expression.  
Expression of CD287 was up-regulated by 53.72% on mature naïve B-cells with TLR 
stimulation, from baseline of 12.77±18.67%, to 19.63±27.05% (p<0.05), however there was 
no change with VIP inhibition even though a definite downward trend was noted (possibly 
owing to the large standard deviation indicating a vast range of data points). While CD284 
expression was not significantly altered by TLR stimulation alone, it was however 
significantly down-regulated in both cases by VIP (with LPS) from 63.69±28.48% to 
30.57±29.96% (p<0.05) and (with R848) 67.23±36.92% to 37.23±31.66% (p<0.05).  
 
3.4.5.2 Inhibitory markers (CD72, CD85j, CD300a, CD305, & CD307d.) and CD95 
In a manner similar to that noted with CD25 expression, CD85j expression on mature naïve 
B-cells, was extremely sensitive to TLR stimulation, with an increase from 1.81±2.42% 
expression at baseline, to 46.98±37.26% with R848 stimulation, representing a >24-fold 
increase (p<0.001; Fig. 3.20 A). Inhibition with VIP resulted in a significant down-regulation 
of expression (p<0.01) to levels not significantly different from that of baseline. Interestingly, 
CD85j expression on the HIV-ve group responded in a similar manner, although with all 
levels <10% (Appendix A, Table 12). CD72 expression on mature naïve B-cells was not 
significantly altered by TLR stimulation, which is consistent with the findings in the activated 
memory B-cell subset. However, VIP inhibition resulted in a significant down-regulation of 
CD72 expression from 38.56±25.58% at baseline to 11.93±9.05% (p<0.01; Fig. 3.20 B). 
CD307d had the lowest expression levels in the mature naïve B-cell subset, and TLR 
stimulation resulted in an up-regulation in CD307d expression on mature naïve B-cells from 
5.95±4.50% at baseline, to 11.05±6.71% (p<0.001; Fig. 3.20 D), while expression was 
significantly down-regulated by VIP inhibition (to 7.17±4.63%, p<0.05). 
As expected, CD95 expression was lowest on this subset at baseline, and experienced the 
lowest mean expression with TLR stimulation. Expression of CD95 on mature naïve B-cells 
was significantly raised by 39.93% with R848 stimulation, from 21.82±25.15% at baseline, to 
30.53±33.70% (p<0.01), while VIP inhibition resulted in a mean CD95 expression that was 
86.21% below baseline, and 90.15% below that of the TLR-stimulated cells (both p<0.05; 
Fig. 3.20 C), which can be considered a near-complete abrogation. As with the majority of 
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markers on the HIV-ve subset, there was no significant change in expression with TLR 
stimulation, and VIP inhibition, and expression in the HIV+ve group was significantly higher in 
all conditions (Appendix A, Table 12). 
In a manner consistent with expression patterns of the previous subsets, both CD305, 
CD300a expression on this subset was not significantly changed by either TLR stimulation, 
or VIP inhibition.  
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Fig. 3.20: Inhibitory (CD85j, CD72), and exhaustion marker (CD307d), and Fas (CD95) expression 
on mature naïve B-cells after R848 stimulation, and VIP inhibition. A) CD85j expression was raised 
approximately 40-fold with R848 stimulation (p<0.001), and decreased back to baseline after VIP 
inhibition. B) CD72 expression on MN B-cells was not significantly changed by R848 stimulation, but 
decreased to levels 69% below that of the un-stimulated baseline (p<0.01). C) Stimulation with R848 
resulted in a 40% increase in CD95 expression, while VIP inhibition resulted in <5% CD95 expression 
(p<0.05). D) CD307d expression on MN B-cells was increased approx. 2-fold with R848 stimulation, while 
VIP inhibition significantly down-regulated expression to levels not significantly different from that of the 
un-stimulated baseline. 
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Fig. 3.21 CD38 expression at baseline, and with both R848 stimulation, and VIP inhibition CD38 
expression was greatest on this subset, and was not very responsive to VIP inhibition A) Baseline CD38 
expression on MN B-cells on HIV+ve patient P168 was 64.74%. B) R848 stimulation increased expression 
of CD38 to 72.40%, although this was not significant. C) VIP inhibition further increased CD38 expression 
on this subset to 77.54%, although the average expression of all the patients in this study had slightly 
decreased CD38 expression with VIP inhibition (60.94±21.49%).  
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Chapter 4 Discussion 
4.1 Whole Blood Ex Vivo phenotyping assay 
HIV+ve individuals have significantly higher baseline activation levels than HIV-ve 
controls 
Previous studies have shown a high incidence of B-cell abnormalities with HIV infection, 
namely hypergammaglobulinemia, polyclonal activation, and poor response to both neo- and 
recall antigen (Penesieroso, et al., 2013; Sciaranghella, et al., 2013; Shen & Tomaras, 
2011). In this study, we assessed the B-cells of asymptomatic HIV+ve individuals in order to 
ascertain their activation and inhibitory/exhaustive status both ex vivo, and after in vitro 
stimulation. The majority of studies have assessed B-cell function in end-stage AIDS, where 
all compartments of the immune system are dysfunctional, we therefore hypothesized that 
our study cohort, with mean CD4 counts of 472.3 cells/µL, would still have a relatively well-
preserved immune system, allowing us to assess the impact of asymptomatic HIV infection 
on the B-cell compartment, with regard to cellular markers of activation, and 
inhibition/exhaustion. Several authors have also reported HIV-associated aberrant B-cell 
activation in asymptomatic HIV-infection (Shen & Tomaras, 2011; Moir, et al. 2008, 2010).  
Our HIV+ve patient cohort did however have increased levels of both CD38, and PD-1 
expression on CD8 T-cells (46.25±22.94% vs. 28.33±17.95%; 31.13±19.79% vs. 
18.29±12.64%, both p<0.0001), indicating that although their immune system could be 
described as “robust” based on CD4 count, there are abnormalities which suggests a 
significantly more activated state with corresponding levels of ‘immune exhaustion’. CD38 
expression on CD8 T-cells is an indirect means of measuring immune activity against viral 
antigens, and as such has proven to be a useful measure of systemic immune activation 
(Sauce, et al., 2013). CD38 expression on CD8 T-cells (CD38/8) also correlated positively 
with HIV plasma viral load (r=0.5147, p=0.041), and negatively with CD4 count (r=-0.4546, 
p=0.038), thereby linking increased HIV plasma viral load with increased immune activation 
levels (CD38/8), and showing the link between immune activation and a decreased CD4 
count 
The aim of the ex vivo phenotyping was to determine whether there was a difference in the 
ex vivo expression of these markers between HIV+ve individuals, and HIV-ve controls. 
Statistics performed on the demographic data of the HIV+ve and control samples showed no 
significant difference in age and sex distributions. Ex vivo activation, exhaustion, or inhibitory 
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marker expression of each of the various B-cell subsets was measured by multicolour flow 
cytometry, and evaluated on the entire B-cell population as well as on each of peripheral 
blood memory B-cell populations. The results demonstrated that B-cells from individuals with 
asymptomatic chronic HIV-1 infection have significantly higher and deregulated ex vivo 
activation, and inhibitory marker expression across all subsets. It was also found that there 
was a general increase in expression of inhibitory markers on activated memory (AMem) 
and tissue-like memory (TLMem) cells in these individuals. In addition, the putative marker of 
exhaustion, CD307d had the highest expression on AMem cells and to a lesser extent, on 
TLMem, and mature naïve (MN) B-cells. Lastly, we assessed ex vivo expression of the 
immunomodulatory receptor, VPAC2, the receptor for vasoactive intestinal peptide and 
found slightly decreased total expression in the HIV+ve group. 
 
4.1.1 Subset Distribution  
Increased “exhausted” B-cells, and a decreased proportion of quiescent cells in 
chronic HIV infection 
Previous studies have noted several perturbations within the B-cell compartment of HIV 
infected individuals (Moir & Fauci, 2008). Notably, there are disturbances in both the number 
of circulating memory B-cells and in the total number of circulating B-cells (Titanji, et al., 
2006). There have been differing opinions on whether the number of circulating B-cells is 
decreased or not with HIV infection, with Fogli, et al. (2012) reporting that there was no 
difference between the median B-cell counts of the HIV+ve or HIV-ve groups (129.5 vs. 143 
cells/µl respectively). Moir, et al. (2008), however reported a significant reduction in median 
absolute B-cell count with untreated HIV infection (171 vs. 270 cells/µl, p<0.0001). 
In concurrence with the study by Moir, the present study found a decreased absolute B-cell 
count (188.6±181.3 vs. 276.8±141.8 cells/µl, p=0.0002; Table 3.1). There was a significant 
reduction in the proportion of RMem B-cells (17.78±7.54% vs. 23.01±8.65%, p=0.0481), and 
a significant increase in the proportion of the putative “exhausted phenotype” TLMem B-cells 
in the HIV+ve group (24.57±14.84% vs. 15.43±10.39%, p=0.0314 respectively). There was 
no significant difference in the distribution of any of the other peripheral blood B-cells, 
although the percentage of AMem B-cells correlated positively with PD-1 expression on CD8 
T-cells, highlighting a possible link between T-cell exhaustion, and B-cell activation and 
exhaustion. Absolute CD4 count correlated positively with the percentage of resting memory 
(RMem) B-cells (r=0.4533, p=0.039), which means that either resting memory B-cells are 
being driven into the activated memory pool, or they are dying via apoptosis, thereby 
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correlating with loss of CD4+ T-cells, which is driven by T-cell activation. This highlights a 
possible mechanistic link between CD4 T-cell loss and re-activation of RMem B-cells. 
Interestingly, there was no significant difference in the number of CD10+ transitional B-cells, 
which is a population that is essentially absent in healthy individuals, but expanded in 
lymphopenic diseases such as HIV infection (Ho, et al., 2006). This may be explained by the 
fact that the patients sampled for this study had relatively well-maintained CD4 counts (mean 
427 cells/µl). Patients from the study by Ho, et al. (2006), with CD4 counts below 50 cells/µl 
had transitional B-cells that accounted for >60% of total B-cells. The decreased proportion of 
resting memory cells can be viewed as being a result of re-activation of this subset, which 
then become activated memory cells, and then due to chronic activation, become 
(functionally exhausted) TLMem cells (Penesieroso, et al., 2013). This is further explained by 
the fact that the percentage TLMem B-cells correlated negatively with the percentage of 
RMem B-cells (r=-0.4844, p=0.26), as well as the percentage of MN B-cells (r=-0.7795, 
p<0.0001).  
As the proportions of MN, and RMem B-cells decrease, the proportion of TLMem B-cells 
increases, indicating the inherent link between the populations. Interestingly, the percentage 
of AMem B-cells correlated positively with the percentage TLMem B-cells (r=0.6532, 
p=0.0013), however, the percentage AMem also correlated negatively with the percentage 
MN (r=-0.8457, p<0.0001) which further strengthens the claim that MN B-cells become 
AMem B-cells upon activation, which in turn become RMem when the activation signals are 
down-regulated (Pensieroso, et al., 2013). The process of down-regulating activation signals 
does not occur with untreated HIV infection, and therefore RMem cells are re-activated, and 
MN cells become AMem, which in turn eventually become functionally-exhausted TLMem 
cells. 
 
4.1.2 The State of the Total B-cell Population ex vivo 
Variable changes in activation marker expression in the HIV+ total B-cell 
population is concomitant with increased inhibitory marker expression 
Total CD25-expressing B-cells were decreased in the HIV+ve group, with 2.42±3.82% 
compared to 4.33±3.38% in the HIV-ve control (p=0.0051). The Il-2 receptor is up-regulated 
with increased IL-2 production, namely by co-stimulated T-cells (Sandoval-Montes & Santos-
Argumedo, 2005). The down regulation of this activation marker is perhaps a result of the 
decreased number of CD4+ T-cells in circulation, or possibly also as a means of 
downregulating response to IL-2, as is found in T-cells. van Grevenynghe, et al. (2011) 
previously described an IL-2 linked pathway of B-cell loss in (untreated) HIV infection, 
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although they defined memory B-cells as being CD3+CD19+CD27+, and did not distinguish 
between AMem, and RMem B-cells, nor did they investigate the entire B-cell population. 
They showed a significant positive correlation between the proportion of memory B-cells and 
serum IL-2 levels (r=0.5801, p<0.0001), although there was no significant difference in CD25 
expression on memory B-cells between HIV+ve subjects, and HIV-ve controls. However, the 
authors did note that interfering with the Foxo3a and TRAIL pathways (both of which are 
linked to IL-2 signaling) is a possible way of rescuing both B- and T-cell function during 
chronic HIV infection (van Grevenynghe, et al., 2011). 
While CD287 expression was not significantly different between the two groups, expression 
of CD284 was significantly raised on the HIV+ve group’s total B-cell population 
(40.86±30.50% vs. 24.56±17.51%, p=0.048), which may be indicative of increased levels of 
systemic LPS, a direct consequence of HIV-associated enteropathy. Moir &Fauci (2009), 
however reported that B-cells do not express LPS receptors, although this may be referring 
to CD14, which is the so-called “classical” LPS receptor that acts as a co-receptor to TLR4. 
CD14 is only found on myeloid antigen-presenting cells such as monocytes and dendritic 
cells, and not B-cells (Murphy, et al., 2008: pp.13). The data here may indicate an additional 
pathway of chronic B-cell stimulation, not previously described. 
Total B-cells expressing CD72 was also increased in HIV+ve group (60.98±19.50% vs. 
38.49±23.68%, p=0.0038). CD72 is expressed on all B-cell subsets except for plasma cells 
and both positively and negatively influences BCR signaling (Wu & Bondada, 2009). Adaci 
et al. (2000) found that CD72 constitutively down-regulates signaling via the BCR, and 
thereby establishes a threshold of signaling for B-cell activation. Several authors have 
reported elevated CD72 expression with HIV infection, however exact figures have not been 
published (Kardava, et al., 2011; Silva, et al., 2011; Moir & Fauci, 2014). Inhibitory receptors, 
also known as immunomodulatory receptors, are critical mediators of immune function, 
which, upon ligation, down-regulate activation signals in order to attenuate an immune 
response (Silva, et al., 2011). In healthy individuals, cell surface receptors bearing 
cytoplasmic ITIMs, negatively regulate activation signals, however in diseases such as HIV, 
the persistent expression of inhibitory receptors can lead to decreased functionality, and 
even anergy and cellular exhaustion (Kardava, et al., 2011).  
 
4.1.3 VPAC2 expression on the total B-cell population 
Vasoactive intestinal peptide is a neurohormone that is part of the glucagon/secretin family, 
whose receptors VPAC1 and VPAC2 are coupled to adenylyl cyclase, which when engaged 
down-regulates cellular production of pro-inflammatory cytokines (such as IL-2) and 
Stellenbosch University  https://scholar.sun.ac.za
 85 
activation markers (Pozo, et al., 2000). VPAC1&2 receptor expression has been well 
described on T-cells, however there has been very little published regarding B-cell 
VPAC1&2 expression (Gaena & Delgado, 2002). Previous studies have determined that 
murine B-cells (at rest, and LPS-stimulated) do not express either VPAC1 or VPAC2 (Lara-
Marquez, et al., 2001). We determined, by use of FMO techniques that B-cells express low 
levels of VPAC2 ex vivo, with significantly down-regulated expression in the HIV+ve group 
(1.07±0.77% vs. 2.26±2.22%, p=0.0296), and that VPAC1 expression was not detected 
(data not shown). We were unable to measure VPAC2 expression on the various B-cell 
subsets due to limitations in fluorochrome availability, and it is possible that even though 
there are low levels of the total B-cell population, there may be increased levels of 
expression on one of the memory B-cell subsets. Therefore it is difficult to infer whether this 
de-regulation of VPAC2 expression is a reflection of HIV-associated immune exhaustion, or 
if it is due to conflicting factors (such as under-, or over-represented populations making up 
the total B-cell compartment).  
4.1.4 The State of Activated Memory B-Cells ex vivo 
A higher proportion of AMem B-cells are terminally-differentiated in chronic HIV, 
but with slightly decreased co-stimulatory capacity 
The HIV+ve AMem subset had markedly increased CD38 expression (38.63±11.82% vs. 
24.21±8.96%, p=0.0097), and slightly decreased CD86 expression (7.09±6.24% vs. 
9.46±5.23%, p=0.048). CD38 is a well-described marker of both T-cell and B-cell activation, 
and in B-cells it is associated with the CD21/CD19 complex, and has been implicated in 
BCR-signaling (Sandoval-Montes & Santos-Argumedo, 2005). CD38 has also been 
identified as a marker of terminal differentiation in B-cells, which has been strongly 
associated with HIV viraemia (Moir & Fauci, 2009). CD86, also known as B7.2 is a marker of 
antigen presentation, and of early activation through T-cell co-stimulation (Pieper, 
Grimbacher, & Eibel, 2013). CD86 is up regulated when CD40 and MHC-peptide complexes 
on B-cells interact with CD40L and the TCR-CD4 complex respectively on T-cells. CD80 and 
CD86 interact with CD28 on T-cells, resulting in the production and release of pro-
inflammatory cytokines such as Il-6 and TNF (Moir & Fauci. 2009).  
One would expect an increase in CD86 expression in the HIV+ve group, similar to that of 
CD38 due to the increased levels of T-cell activation; however CD86 was only up regulated 
upon antigen stimulation. It is known that the CD38 pathway is intrinsically different to that of 
the CD86 pathway: CD38 is up-regulated upon mature naïve B-cell activation and 
differentiation (Sandoval-Montes & Santos-Argumedo, 2005). Whereas, in support of the 
current study findings, Malaspina, et al. (2010) reported impaired co-stimulatory capacity in 
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the B-cells of HIV-viraemic individuals, manifest as a decreased expression of the CD80 & 
CD86 receptor pair. 
 
Variable inhibitory receptor expression on AMem B-cells in the HIV+ve group, but 
significant exhaustion marker CD307d expression 
In the HIV+ve activated memory subset, CD72 was found to be elevated (33.33±20.08%, vs. 
20.74±17.66%, p=0.0396), while CD300a and CD305 had decreased expression in the 
HIV+ve group (60.91±17.88% vs. 70.74±11.26%, p=0.048; & 19.67±10.17% vs. 
29.89±13.64%, p=0.0213 respectively). Silva, et al. (2011) reported that CD300a expression 
is mostly absent on mature naïve B-cells, and variably-expressed on memory cell and 
plasmablast/cell subsets. The same authors also stated that CD305 expression is lowest on 
the memory subsets, and highest on mature naïve B-cells, and that CD307d is almost 
absent on mature naïve B-cells, and mainly expressed on the tissue-like memory subset 
(Silva, et al., 2011). In the context of HIV-infection however, it was reported that markers like 
CD85j (which is mostly absent in healthy individuals), CD300a, and CD305 are aberrantly 
expressed with untreated infection and concomitant with the expansion of the exhausted 
tissue-like memory phenotype (Moir, et al., 2008). 
The data in the present study supports that of Silva, et al. (2011), where CD300a and CD305 
expression was down-regulated with HIV-infection. CD305 recognises collagen as its 
primary ligand, suggesting a potential role in regulation of tissue damage and inflammation 
(Meyaard, 2008). Furthermore, CD300a has recently been identified as a receptor for 
phosphatidylserine and phosphatidylethanolamine, which are both expressed on cell surface 
with cell death (Simhadri, et al., 2012). Indeed, the fact that both CD305 and CD300a are 
down-regulated, while CD72 remains up-regulated, seems to be rather counter-intuitive, due 
to the increased inflammation and immune activation seen in HIV infection (Klatt, et al., 
2013). This is perhaps indicative of the state of AMem B-cells in untreated HIV infection, 
where there is dysfunctional BCR signaling (due to up-regulation of markers which have 
opposing effects thereon), and where at least a quarter of all AMem B-cells express the 
exhaustive marker CD307d.  
In healthy individuals, insignificant levels of inflammation (lower CD38/8) were found 
alongside higher levels of CD305 and CD300a, both of which could play a role in the 
clearance of damaged and apoptotic tissue. Decreased levels of CD305 and CD300a in HIV 
infection may therefore contribute towards increased levels of inflammation (as indicated by 
increased CD38/8), a fact that may be further influenced by increased expression of both 
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inhibitory, and exhaustion markers. These cells may consequently be entering a state of 
exhaustion, and have BCR function that is inhibited, thereby also inhibiting effector functions 
such as responding to tissue damage, and interacting with T-cells via co-simulation.  
4.1.5 The State of Tissue-Like Memory B-cells ex vivo 
Putative exhaustion marker CD307d expression is primarily associated with 
AMem, not TLMem B-cell in chronic HIV infection 
CD307d is technically an inhibitory receptor, bearing intracellular ITIMs, which was initially 
discovered in a population of CD21lowCD27low human tonsillar cells, and subsequently in 
peripheral blood in CD21lowCD27low “tissue-like” memory B-cells (Moir, et al., 2008). These 
tissue-like memory B-cells have been shown to express a homing and inhibitory receptor 
profile similar to that of the antigen-specific exhausted T-cell phenotype, and the same 
authors have demonstrated that this population of B-cells proliferates poorly in response to 
B-cell stimuli, and have a predominantly HIV-specific response (when comparing challenge 
with influenza haemagglutinin and HIV gp120) (Moir, et al., 2008). Contrary to literature 
findings, we demonstrated that FcRL4 (CD307d) was present mainly on activated memory 
cells and to a lesser extent on tissue-like memory cells and mature naïve B-cells of both 
HIV+ve and HIV-ve individuals; and not primarily on HIV+ve tissue-like memory cells. CD307d 
expression was significantly up-regulated in activated memory cells (25.75% vs. 15.27%, 
p=0.0015), tissue-like memory cells (12.93±10.32% vs. 7.50±5.10%, p=0.045), and mature 
naïve B-cells (7.49% vs. 2.58%, p=0.014). Until recently, the ligand for CD307d was 
unknown, until Wilson, et al. (2012) implicated IgA as the primary ligand for FcRL4, thereby 
proving its status as a genuine Fc receptor. 
TLR activation pathways are up-regulated with HIV infection 
TLRs are involved in recognition of highly-conserved pathogen-associated molecular 
patterns (PAMPs), of which TLR7 (CD287) recognises internalised viral single-stranded RNA 
within endosomes, while TLR4 (CD284) recognises bacterial LPS. CD287 expression was at 
1.12±1.32% in the HIV-ve group, while there was an approximate 8-fold increase in the 
HIV+ve group (p=0.0128); while CD284 expression was relatively similar between the two 
groups (medians approx. 27%). Persistent viraemia and bacterial translocation are both 
hallmark features of untreated chronic HIV-infection, thereby possibly explaining the 8-fold 
increase in CD287 expression in the HIV+ve group, but not the unchanged CD284 
expression (Klatt, et al., 2013; Moir & Fauci, 2014). It is possible that exposure to LPS 
causes a downregulation of CD284 expression, however, there may also be an as yet 
unknown bacterial mechanism of B-cell exhaustion that is separate to the TLR pathway. 
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Tissue-like memory B-cell have down-regulated BCR function, and increased 
expression of a leukocyte immunoglobulin-like receptor (LILRs) 
LILRs consist of several immunomodulatory receptors whose function is to regulate the 
effector functions of professional APCs, most importantly immune activation in a variety of 
disease contexts, such as HIV infection (Lichterfeld & Yu, 2012). The same authors reported 
that the function of CD85j is to down-regulate immune responses via phosphorylation of 
intracellular ITIM domains (Lichterfeld & Yu, 2012). Expression of CD85j on B-cells (which is 
effectively absent from healthy individuals) is linked to BCR signaling, and a decreased 
memory B-cell response (i.e. proliferation and antibody secretion) during HIV (Sauce, Elbim, 
& Appay, 2013). CD85j expression was increased almost 3-fold on the TLMem subset with 
HIV infection (19.38±23.18% vs. 7.09±10.39% p=0.0463). CD72 expression was also 
increased in the HIV+ve TLMem subsets (70.88±16.54% vs. 28.83±25.68%, p<0.0001). Both 
these receptors have been shown to down-regulate BCR signaling, and their expression on 
this subset is indicative of decreased functional capacity, and therefore immune exhaustion. 
Moir & Fauci (2010) reported an increase in CD95 expression with HIV infection, and while 
one would expect this population to be pre-disposed to apoptosis, CD95 expression was not 
significantly different between the two groups. It did, however approach significance 
(27.49±16.27% vs. 19.37±17.70%; p=0.0783), and a larger sample size may yield significant 
results. 
4.1.6 The State of Resting Memory, & Mature Naïve B-cells ex vivo 
Patterns of marker expression indicate apparent increased antigenic stimulation, 
both directly (via TLR pathways), and indirectly (via IL-6 signaling) in resting 
memory B-cells 
As previously mentioned, the relative proportion of resting memory cells was significantly 
decreased in the HIV+ve group. In addition, there was a significant increase in activation 
marker expression within this subset, with increased CD126, CD287, and CD284 expression 
compared to the HIV-ve control (39.01±25.59% vs. 14.89±9.48%, p=0.0008; 10.60±13.10% 
vs. 3.44±2.61%, p=0.0199; & 51.43±30.12% vs. 24.84±10.07%, p=0.0057). IL-6, the ligand 
for CD126, is up-regulated with B-cell activation and plays an important role in maturation of 
activated B-cells (Baenziger, et al., 2009). Constant antigenic stimulation, which is 
characteristic of HIV-infection, results in increased B-cell activation and proliferation, which is 
due, in part to increased serum IL-6 concentration (Leeansyah, et al., 2013). This may be a 
likely mechanism for the increased CD126 expression in this subset, due to the fact that 
resting B-cells should not have high CD126 expression. CD126 expression was also 
markedly increased on the HIV+ve mature naïve B-cell subset, which accounted for the 
majority of B-cells within both HIV+ve and HIV-ve individuals (43.56±17.33% vs. 
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49.03±18.20% of total B-cells). 21.56±32.25% of HIV+ve mature naïve B-cells expressed 
CD126 (compared to 5.91±7.83% in the HIV-ve control p=0.024), which is a direct 
consequence of chronic B-cell stimulation-related IL-6 release. Indeed, in healthy individuals, 
mature naïve B-cells express very low levels of activation markers due to the fact that they 
are cognate Ag naïve, and mount weak responses to innate stimuli. These cells can also be 
in the early stages of activation, which requires both BCR-stimulation and T-cell help 
(Ruprecht & Lanzavecchia, 2006). These mature naïve B-cells, in a sense, have a 
predisposition towards activation at a very early stage, a state that may very well be a major 
contributing factor towards HIV-associated B-cell dysfunction. 
In agreement with Lanzavecchia & Sallusto (2007), mature naïve B-cells in our HIV+ve cohort 
lacked TLR4 expression. The same authors stated that antigen naïve B-cells only express 
TLR7 when primed by APCs such as DCs (Lanzavecchia & Sallusto, 2007). This is in 
concert with our finding of consistent up-regulation of CD287 across all B-cell subsets 
(except for the mature naïve subset, on which there are extremely low levels of expression) 
is highly indicative of persistent viraemia. Similarly, CD284, the LPS-recognizing TLR, had 
up-regulated expression on resting memory cells, and not mature naïve B-cells, indicating 
prior exposure to LPS. 
5.2 Responses of isolated B-cells to R848, LPS, and VIP  
B-cells enriched by negative selection were cultured for 18 hours with either LPS or R848 
alone, or in combination with VIP (hereafter referred to as “VIP inhibition”). B-cells from 
HIV+ve individuals had a higher activation status after culture along with an increased 
inhibitory and exhaustive phenotype compared to that of the HIV-ve control group. We further 
showed that HIV+ve B-cells are more sensitive to TLR stimulation than HIV-ve controls and 
that in certain instances, VIP inhibition results in alteration of receptor expression to levels 
similar to that of the HIV-ve control. In other words, compared to the stimulated conditions, 
co-incubation with VIP resulted in significant down-regulation of activation, inhibition, and 
exhaustion marker expression. We also demonstrated that B-cells express a functional LPS 
receptor in the form of TLR4, in contrast to previous reports which suggest  that B-cells do 
not express LPS receptors (Moir & Fauci, 2009) 
Innate stimuli such as LPS and R848 (an agonist for TLR7, which is the innate sensor of 
viral RNA) were used in this assay to represent two important contributing arms of chronic 
stimulation by HIV, namely indirectly, via increased systemic LPS and directly, via viraemia 
respectively. B-cells in the current study displayed varying expression of markers of 
activation (increased CD126 in RMem cells and decreased CD86 and CD25 expression on 
AMem cells). In fact, it is well known that the HIV+ve immune system has a higher baseline 
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activation status than that of healthy individuals, and as such have a predisposition towards 
cellular activation (Appay & Sauce, 2009). The fact that TLR-mediated activation of antigen-
naïve B-cells occurs predominantly after CD40 and BCR activation is indeed supported by 
our data, in that our TLR ligands effectively induced activation and inhibitory marker 
expression (Allman & Pillai, 2008).  
5.2.1 Subset Distribution 
TLR stimulation has litt le effect on B-cell subset distribution in vitro 
The TLR stimulation data support the ex vivo findings of a decrease in the relative 
percentage of resting memory cells in the HIV+ve group across the stimulation conditions 
compared to the HIV-ve control. The different stimulation conditions had little effect on overall 
subset distribution, although there was a trend towards a decrease in the HIV-associated 
subsets (tissue-like memory, and transitional B-cells) with VIP inhibition, as well as an 
increase in the proportion of resting memory and mature naïve B-cells, however this was 
statistically insignificant.  
5.2.2 The Total B-cell Population after TLR Stimulation and VIP Inhibition 
R848 provided the best stimulation for total B-cells and resulted in up-regulated 
activation marker expression 
CD38 and CD86 are markers of activation, where CD38 is a marker of terminal B-cell 
differentiation, and CD86 a marker of co-stimulatory ability (Moir & Fauci, 2009). CD86 
expression was significantly lower than baseline after VIP inhibition (p<0.01), and was also 
not significantly different from the HIV-ve group in the same conditions. VIP therefore was 
able to down-regulate CD86 expression on the total B-cell population to levels that are 
similar to that of the HIV-ve group. In the presence of VIP the total B-cell population would 
therefore be at a lower state of activation, and be less likely to prime T-cells via co-
stimulation, thereby contributing towards lowering T-cell activation in HIV infection. CD38 
expression on the total B-cell population appears to be largely expressed on mature naïve B-
cells, as it is supposedly lost on mature lymphocytes (Deaglio, et al., 2003). Furthermore, 
Deaglio, et al. (2003) reported that CD38 appears to have maturation stage-, and 
microenvironment-specific function, where it is involved in lymphopoeisis blocking in the 
bone marrow, and down-regulating apoptosis in germinal centre B-cells. Perhaps, the fact 
that CD38 is up-regulated with VIP inhibition indicates that its function on mature 
lymphocytes concerns apoptosis regulation, and up-regulated expression confers a 
protective effect on the B-cell population. Sandoval-Montes and Santos-Argumedo (2005) 
demonstrated that CD38 is also associated with the CD21/CD19 complex and plays a role in 
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BCR signaling. Up-regulated CD38 expression in this instance may confer more tightly-
regulated BCR signaling and function. 
 
TLR4 (CD284) and TLR7 (CD287) expression is down-regulated with VIP 
inhibition in total B-cell populations, as well as in all measured subsets 
Interestingly, CD287 expression on the total B-cell population was unresponsive to R848 
stimulation, whereas CD284 expression was responsive. Inhibition with VIP resulted in a 
highly significant down-regulation of receptor expression to levels that were both below 
baseline, and insignificantly different from that of the HIV-ve population. The same was true 
for CD284 and CD287 expression of AMem, RMem, TLMem, and MN B-cells in the HIV+ve 
group, with the VIP inhibition scenarios having the lowest expression within the HIV+ve group 
alone. Interestingly, CD284 also has low baseline expression on mature naïve B-cells in the 
HIV-ve group compared to that of the HIV+ve group, indicating that HIV+ve individuals have 
high systemic LPS, and subsequently, higher levels of activation marker expression. 
Stimulation for 8 hours with TLR agonists has been shown to up-regulate mRNA levels of 
genes critical to B-cell proliferation and differentiation (Hanten, et al., 2008). Lester, et al. 
(2008) have also shown increased TLR4 and TLR7 expression on PBMCs isolated from 
HIV+ve women from Kenya, both of which correlated with HIV viraemia, and also that TLR 
expression levels returned to levels comparable to HIV-uninfected individuals with the 
initiation of ART. This study however, also measured TLR-mRNA levels, and not direct 
expression on cells, and therefore also did not investigate TLR expression on each cell 
subset. Furthermore, Baenziger, et al. (2009) found that chronic TLR7 stimulation in mice 
induces similar immune activation and lymphoid system disruption to that of HIV infection. 
Their findings indicate that TLR7 plays a major role in HIV-mediated pathology, and our data 
suggests that administration of VIP in a dose of 1 x10-8M can significantly reduce TLR7 
expression across all B-cell subsets to levels not dissimilar to that of HIV uninfected 
individuals. To our knowledge, this is the first study to investigate TLR expression after 
stimulation, via multicolour flow cytometry, as well as to investigate the effect of VIP 
inhibition on the expression of TLR7 (CD287) and TLR4 (CD284). 
Although the LPS-recognizing TLR, CD284, had down-regulated expression in presence of 
VIP, there were still approx. 48% of total B-cells expressing this receptor. These levels, 
however were not significantly different from that of the HIV-ve group, and little is known as to 
the expression patterns of TLR4 on B-cells in HIV infection (and healthy individuals), so it is 
difficult to draw a clear conclusion from these results. It may be likely that CD284 expression 
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is in fact downregulated in response to high levels of systemic LPS. A recent study by 
Rauch, et al. (2012) described CD284 expression on B-cells in the context of sepsis, and 
they reported constitutive expression of this LPS receptor. 
 
VPAC 2 expression, although somewhat higher on the B-cells of HIV-ve 
individuals, is not effected by TLR stimulation 
VPAC2 expression on the total B-cell population tended towards having higher expression in 
the HIV-ve group, although this was not statistically significant. Due to limitations in antibody 
availability, we were unable to determine VPAC2 expression on the different B-cell subsets, 
although pilot data (not shown) did indicate that VPAC2 was expressed only on CD19+CD21- 
B-cells, thereby excluding resting memory and mature naïve B-cells. It is most likely that 
VPAC 2 expression is up-regulated upon activation, and therefore would be present on 
plasmablasts, activated memory, and perhaps tissue-like memory cells. According to our 
data, the other cell types responded to VIP inhibition, so further studies into the dynamics of 
VPAC2 expression on the B-cell subsets is warranted. Indeed, VPAC2 levels on CD4+ T-
cells correlated positively with Fas ligand (FasL) expression (Ipp, et al., 2014). It is possible 
that the fact that there is no de-regulation of VPAC2 expression with HIV infection, indicates 
that it could be a potential therapeutic target.  
Molecular studies have elucidated that lymphocytes may indeed be producers of VIP, along 
with peptidergic nerve fibres in the lymphoid tissue, whose downstream effects include 
inhibition of pro-inflammatory cytokines such as IL-6, and IL-12; and later stimulation of anti-
inflammatory IL-10 production (Pozo, et al., 2000). 
Markers of inhibition were down-regulated by VIP inhibition 
Expression of CD72 was significantly lowered by LPS, and not R848 stimulation, while 
CD85j, and CD305 expression was not significantly changed by either. VIP inhibition 
resulted in significant further down-regulation of CD72 and CD85j; however this was still 
significantly higher than that of the HIV-ve group. Based on this data, CD72 expression 
seems to be reversible to a certain extent, although additional studies may be required to 
elucidate the significance of this. CD72 seems to be involved in setting the threshold for 
BCR-mediated activation, so down-regulation of this marker may prove useful in 
counteracting activation-mediated cellular exhaustion (Adaci et al., 2000). This could indicate 
that B-cells, even in asymptomatic HIV infection, have progressed to the stage where 
markers of exhaustion are prominent on the total B-cell population, and that some of these 
markers remain elevated even with VIP inhibition.  
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The apoptotic receptor CD95 (Fas) was down-regulated by VIP  
CD95 expression on the total B-cell population responded strongly to R848 stimulation, and 
was significantly down-regulated with VIP inhibition. The high baseline levels of CD95 on this 
population was indicative of an increased propensity towards apoptosis (43% of cells 
expressed CD95). The subsequent increase in CD95 expression with TLR stimulation further 
strengthens this hypothesis. Therefore, VIP has shown efficacy in down-regulating CD95 
expression on the total B-cell population (to levels similar to that of healthy individuals), and 
has the potential to play an important role in ameliorating the effects of chronic HIV infection.  
 
5.2.3 The State of Tissue-Like Memory B-cells  
The exhausted B-cell population displayed evidence of viral, and bacterial 
stimulation, and VIP was unable to down-regulated activation marker expression  
CD287 expression was absent on TLMem B-cells in the HIV-ve group, and VIP inhibition 
elicited the same response in the HIV+ve group. More than 60% of TLMem B-cells expressed 
CD284 at baseline, while VIP inhibition down-regulated expression to levels comparable with 
the HIV-ve control. The high expression levels of these two markers at the un-stimulated 
baseline, as well as the up-regulation of CD287 with stimulation indicates that this population 
has had prior antigenic stimulation via LPS and viral RNA, and it primed to respond rapidly to 
viral RNA. This supports the findings that viraemeia contributes towards B-cell exhaustion 
(Kardava, et al., 2011; Moir & Fauci, 2009).  
 
The exhausted B-cell population displayed evidence of inhibited BCR signaling 
as well as increased apoptotic potential, and appeared unable to fully recover 
with VIP inhibition 
Inhibitory marker expression was up-regulated at baseline on TLMem B-cells (where the 
HIV-ve group had <1% expression of inhibitory receptors). CD72, CD300a, CD307d, and 
CD85j expression was slightly down-regulated upon VIP inhibition; however levels of these 
markers never reached levels comparable to that of the HIV-ve group. Similarly, CD95 
expression on this subset remained significantly raised (compared to the HIV-ve control) even 
after VIP inhibition. The TLMem B-cell population was therefore unable to fully recover from 
its inhibitory and pro-apoptotic state with VIP inhibition. The tissue-like memory population 
can indeed be regarded as being functionally “exhausted”, in that their inhibitory state 
persisted, even after our intervention. These cells are therefore beyond the point where they 
could be rescued from their fate, and an intervention should rather be targeted at B-cells 
before they become exhausted.  
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CD307d expression was somewhat insensitive to TLR stimulation in the HIV+ve 
group 
The putative marker of B-cell exhaustion, CD307d was equally sensitive to both LPR and 
R848 stimulation, although, there was only a significant reduction in expression with LPS & 
VIP inhibition, where the HIV+ve mean expression was comparable to that of the HIV-ve 
group. This was observed in mature naïve, tissue-like memory, and activated memory B-
cells, while although there was a trend towards down-regulated expression with VIP 
inhibition, this was not statistically significant. Total B-cell CD307d expression was, however, 
down-regulated with both dual-stimulation events, although not in any of the three subsets 
individually. 
FcRL4 may act as a molecular switch in memory B-cells, which down-regulates adaptive 
immune signaling, and up-regulates the innate response in reaction to chronic antigenic 
stimulation, as seen in untreated HIV infection (Sohn, et al., 2011). This explains the similar 
CD307d response in both LPS, and R848 stimulation, although it leads one to wonder why 
VIP only down-regulates this marker in LPS-stimulated cells, and not in R848-stimulated 
cells. It is possible that like LPS, VIP binds to a receptor on the cell surface, while ligands for 
TLR7 are intracellular (via endosomal transportation), and therefore R848 stimulated cells 
are activated in a manner that is intrinsically different to that of the LPS stimulated cells.  
 
5.2.4 The State of Mature Naïve, and Activated and Resting Memory B-cells  
Activated memory B-cells responded to VIP inhibition and down-regulated 
almost all activation and inhibitory markers 
AMem B-cells at baseline displayed evidence of prior antigenic stimulation, as well as 
increased cellular activation as measured by CD86, and CD126 expression. The exhaustive 
status of these cells was also high, due to increased expression of multiple inhibitory 
markers. AMem B-cells in the HIV+ve group were able to down-regulate TLR4 and TLR7 
expression, as well as CD86, CD72, CD305, and CD95, after VIP inhibition. Therefore the 
phenotype of these cells returned to one that is comparable with the HIV-ve group. CD126, 
and CD307d, however remained elevated, even after VIP inhibition. This is perhaps 
indicative of the fact that CD126 expression is required for activation of resting memory B-
cells (Haas, et al., 2011); while cellular exhaustion (as measured by CD307d expression) 
remained higher (although only marginally so, where p=0,034). Perhaps a higher dose of 
VIP is needed to down-regulate expression of CD307d, or indeed an additional signal may 
be required to down-regulate its expression. What is quite interesting is that there was a 
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near complete down-regulation of CD95 expression post VIP inhibition (p<0.05), indicating 
that the apoptotic potential of these cells was essentially similar to that of the HIV-ve group. 
 
Resting memory B-cells responded the most efficiently to VIP inhibition, with 
near complete down-regulation of activation, and inhibitory markers. 
RMem B-cells at baseline also displayed evidence of prior antigenic stimulation, as well as 
increased cellular activation as measured by CD25, CD86, and CD126 expression. The 
exhaustive, and pro-apoptotic status of these cells was also high, due to the expression of 
CD307d, CD305 and CD95. All markers were down-regulated upon VIP inhibition, and 
interestingly, CD25 expression (the IL-2 receptor) was down-regulated to levels below that of 
the HIV-ve control. RMem B-cells could therefore prove to be an effective therapeutic target 
in early HIV infection, as these are the cells that become re-activated upon stimulation 
(hence their depletion).  
 
Mature Naïve B-cells responded to VIP inhibition, although several of activation, 
and inhibitory markers remained up-regulated  
It is interesting to note that this subset was able to down-regulate most activation and 
inhibitory markers upon VIP inhibition (despite having a pre-disposition towards activation, 
as indicated by their response to TLR ligands). MN B-cells in the HIV-ve group did not 
respond to TLR stimulation, and indeed, should not, due to the fact that there was no prior 
BCR engagement (mature naïve B-cells are by definition, naïve to BCR engagement). VIP 
inhibition was unable to down-regulate CD126 expression, indicative of the prior IL-6 
stimulation in vivo. Similarly, CD307d, and CD95 expression remained up-regulated post VIP 
inhibition, which is perhaps indicative of a predisposition towards cellular exhaustion, and 
early apoptosis signaling in HIV infection. CD85j, an Ig-like receptor, had insignificant 
baseline expression, but was markedly up-regulated with R848 stimulation, and returned to 
baseline levels with VIP inhibition. This also shows the underlying predisposition towards 
activation in HIV infection, due to the lack of a similar response in the HIV-ve group. 
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5.3 Limitations of the Study, 
A major limiting factor if this study was the small sample size, which can be attributed to the 
high cost associated with multicolour flow cytometry. This study has proven which novel 
markers are expressed significantly, so future studies may be able to decrease costs by 
reducing the number of antibodies required. A further limitation is that we only investigated 
surface marker expression, and not intracellular mRNA levels, which would give a more 
accurate depiction of gene upregulation. TB co-infection is a major problem in the HIV+ve 
population, so investigating the effects of both TB-HIV co-infection, and mono infection 
would be of significance in future studies.  
 
5.4 Concluding Remarks 
This study has demonstrated that, ex vivo, B-cells from HIV+ve individuals have significantly 
higher expression of both activation and inhibitory markers, as well as low levels of the 
immunomodulatory receptor, VPAC2. There was a profound loss in both the absolute 
number of circulating B-cells, as well as the number of resting memory cells in HIV infection 
and concomitantly, an expansion of a tissue-like memory phenotype, which has been shown 
to display a similar phenotype to that of the exhausted T-cell. Thus even in this group of 
clinically well HIV+ve participants, with relatively well maintained CD4 counts; significant B 
cell abnormalities can be detected. Earlier administration of antiretroviral therapy possibly in 
conjunction with an immune-modulatory agent such as VIP, may limit the dysfunction that 
develops in the B cell compartment.  
We have also shown that isolated B-cells are extremely responsive to TLR stimulation in 
vitro, with high expression of receptors that recognize LPS, and viral RNA. We proved that 
LPS can effectively activate B-cells in vitro, despite contrary reports in literature, although 
R848-stimulation was more effective than that of LPS. Mature naïve B-cells from HIV+ve 
individuals had a predisposition towards activation such that they were able to up-regulate 
activation markers after stimulation while those in the HIV-ve group did not. Furthermore, we 
provided evidence for the potential role of vasoactive intestinal peptide as an 
immunomodulatory agent in a concentration of 1 x10-8 M. Inhibition with VIP with either of 
the TLR-ligands (LPS or R848) significantly down-regulated both activation marker (CD126, 
CD86), and inhibitory marker (CD85j, CD300a) expression on various B-cell subsets. VIP 
was also able to down-regulate CD95 expression on all subsets of HIV+ve B-cells (except for 
activated memory cells). Our data has shown that VIP appears to almost completely inhibit 
pathway-specific activation pathways (through CD86 expression, and not CD38), while it 
Stellenbosch University  https://scholar.sun.ac.za
 97 
was able to nearly-completely downregulate CD95 expression, and therefore Fas-mediated 
apoptosis signaling. 
Inhibition with VIP resulted in CD287 expression indistinguishable from that of an HIV-ve 
individual, thereby proving its ability to dampen the potential harm of persistent viraemia, by 
down-regulating the innate viral sensors on these B-cells. Silva, et al. (2011) reported that 
CD305 expression is lowest on the memory subsets, and highest on mature naïve B-cell ex 
vivo, which supports our earlier findings, however this was practically reversed with culture 
and stimulation of cells, where mature naïve B-cells consistently express the lowest levels of 
the collagen receptor, CD305. Perhaps it is useful to down-regulate CD305 expression on 
the antigen-specific memory subsets to limit the already present propensity towards 
inhibition and exhaustion. The fact that there was no response in mature naïve cells is 
perhaps indicative of their lack of BCR engagement.  
The marker of exhaustion, CD307d was significantly higher on the tissue-like memory and 
activated memory subsets of the HIV+ve group, even after VIP inhibition. It appears that in 
most cases, the HIV+ve TLM subset is past the proverbial “point-of-no-return” for VIP to 
effectively down-regulate activation and inhibition markers. Further studies may shed light 
onto this, and in fact one could expect to see a decrease in the numbers of TLM cells, with 
VIP, as is seen with ART. Mature Naïve B-cells should be the primary target of a subset-
specific intervention, due to the fact that these cells have had the least exposure to 
stimulation of any peripheral blood subset. 
Currently in South Africa, the guidelines for commencing ART are at a CD4 count of 
350cells/µl. This study has shown clearly that even at CD4 counts above this level; 
significant B cell abnormalities and dysfunction have already occurred in vivo. It would 
therefore be important for earlier interventions to take place to determine which patients 
have a more ‘activated and/ or exhausted’ phenotype; targeting them for earlier therapies. 
This study also highlighted the potential for a novel immune-based intervention strategy with 
the use of the agent VIP. Future studies may benefit from investigating the effects of 
different types of stimulation (i.e. cognate Ag, de novo Ag, mitogen stimulation). 
Furthermore, while propensity towards apoptosis signaling was only measured via Fas cell 
surface expression, future studies may further benefit from investigating the various 
apoptosis pathways (via caspase activation, bcl signaling, and even NK-mediated cell killing) 
and the endpoints of apoptosis, such as Annexin V expression. 
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